≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Motor disorders, excluding more controls

Endpoint Browser PheWeb

KRA_PSY_MOTOR_EXMORE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

None

-

2. Check conditions

None

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — F82
  • Hospital discharge: ICD-9 — 3154A
  • Cause of death: ICD-10 — F82
  • Cause of death: ICD-9 — 3154A

2 out of 7 registries used, show all original rules.

-

4. Check minimum number of events

None

-

5. Include endpoints

None

-

6. Filter based on genotype QC (FinnGen only)

None

-

Control definitions (FinnGen only)

Control exclude
KRA_PSY_ANYMENTAL

Extra metadata

First used in FinnGen datafreeze
DF2
Parent code in ICD-10
F80-F89
Name in latin
Perturbatio specifica progressus functionis motoricae

Case counts by codes

↥

FinnGen case counts by registry codes:

No upset plot: script not run.

No upset table: script not run.

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 19285 5193 14091
Only index persons 14350 3746 10604
Unadjusted period prevalence (%)
Whole population 0.33 0.15 0.39
Only index persons 0.34 0.14 0.40
Median age at first event (years)
Whole population 5.64 5.23 5.79
Only index persons 6.01 5.73 6.11

-FinnGen-

Key figures

All Female Male
Number of individuals 574 239 335
Unadjusted period prevalence (%) 0.12 0.08 0.15
Median age at first event (years) 6.11 6.06 6.14

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
621
Matched controls
5820
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F82
ICD-10 Finland
Specific developmental disorder of motor function
16384.0
307.7
585
*
Z2445
NOMESCO Finland
Psychologist
26.7
248.8
196
99
R62.0
ICD-10 Finland
Delayed milestone
36.8
219.7
150
50
XA800
NOMESCO Finland
Neuropsychological investigation
26.0
214.9
168
82
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
38.8
200.7
134
41
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
13.3
180.6
212
219
F83
ICD-10 Finland
Mixed specific developmental disorders
2211.5
178.4
168
*
F90.0
ICD-10 Finland
Disturbance of activity and attention
13.5
160.9
180
171
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
16.1
159.9
157
120
R4120
NOMESCO Finland
Occupational therapy
16.7
145.9
138
98
N05AH04
ATC
quetiapine; oral
14.2
136.2
142
119
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
9.6
129.0
187
250
Z3226
NOMESCO Finland
Physiotherapist
7.3
124.2
260
523
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
10.7
123.3
159
182
ZY010
NOMESCO Finland
Hospital outpatient
15.4
123.1
120
89
Z2446
NOMESCO Finland
Social worker
8.4
116.5
189
287
F80.1
ICD-10 Finland
Expressive language disorder
642.6
115.3
113
*
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
21.2
108.2
88
45
IGY02
NOMESCO Finland
Psychiatric monitoring contact
17.2
99.1
89
56
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
12.4
99.0
109
98
IGY99
NOMESCO Finland
Other psychiatric treatment contact
26.6
98.9
73
29
N06BA04
ATC
methylphenidate; oral
9.9
98.7
130
151
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
59.9
97.6
58
10
F32.9
ICD-10 Finland
Depressive episode, unspecified
9.6
93.7
126
150
IBA01
NOMESCO Finland
Diagnostic and symptom-mapping evaluation
40.6
91.3
59
15
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
172.6
89.6
94
6
IBA04
NOMESCO Finland
Extensive initial psychiatric evaluation
36.0
83.9
56
16
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
19.3
83.3
70
38
N05AX08
ATC
risperidone; systemic
138.7
83.2
89
7
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
123.0
83.2
90
8
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
19.8
81.8
68
36
F80.2
ICD-10 Finland
Receptive language disorder
227.1
81.4
84
*
IGP01
NOMESCO Finland
Psychiatric family contact
31.9
81.1
56
18
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
10.2
79.2
99
106
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
12.7
78.0
83
70
Z2221
NOMESCO Finland
Medical doctor
5.0
77.9
235
627
R4110
NOMESCO Finland
Physiotherapy
4.9
77.0
249
702
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
796.0
76.2
75
*
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
9.5
76.1
101
117
N05AH03
ATC
olanzapine; systemic
112.0
76.0
83
8
Z3231
NOMESCO Finland
Registered nurse
4.5
74.4
302
1010
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
9.8
74.1
95
105
R5599
NOMESCO Finland
Other rehabilitation service
25.8
71.5
53
21
F81.3
ICD-10 Finland
Mixed disorder of scholastic skills
736.0
70.9
70
*
N03AX09
ATC
lamotrigine; oral
25.2
69.6
52
21
N05AX12
ATC
aripiprazole; systemic
365.3
69.4
70
*
F80.9
ICD-10 Finland
Developmental disorder of speech and language, unspecified
249.9
69.1
71
*
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
14.6
68.3
66
47
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
10.0
65.7
82
87
F81.0
ICD-10 Finland
Specific reading disorder
36.0
64.6
43
12
ZXE10
NOMESCO Finland
More than one and less than three hours
4.2
63.8
250
799
N03AG01
ATC
valproic acid; systemic, rectal
12.7
63.7
67
55
F29
ICD-10 Finland
Unspecified nonorganic psychosis
653.8
63.5
63
*
Z3229
NOMESCO Finland
Other healthcare associate professional
6.2
62.2
125
229
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
19.2
61.1
51
27
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.4
59.5
199
562
IDY03
NOMESCO Finland
Systematic individual therapy, cognitive-behavioural
31.6
59.3
41
13
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.0
56.9
115
211
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
83.5
56.6
64
8
RT160, ,
NOMESCO Finland
21.6
54.3
43
20
T36
ICD-10 Finland
Poisoning by systemic antibiotics
25.9
52.9
39
15
N06AB03
ATC
fluoxetine; oral
10.6
52.8
62
60
ZXE20
NOMESCO Finland
More than three and less than five hours
5.6
52.7
116
230
ZXD10
NOMESCO Finland
Scheduled procedure
3.6
52.0
280
1085
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
16.5
51.4
46
28
R4130
NOMESCO Finland
Speech therapy
12.2
50.7
54
45
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.8
50.7
106
200
Z01.1
ICD-10 Finland
Examination of ears and hearing
4.1
49.8
176
511
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
8.7
49.6
68
81
Z50.5
ICD-10 Finland
Speech therapy
7.3
49.4
80
116
R56.8
ICD-10 Finland
Other and unspecified convulsions
5.9
49.1
99
180
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
+∞
48.4
47
*
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.8
48.2
202
659
IFA01
NOMESCO Finland
Psychiatric pharmacotherapy plan, not specified
484.3
47.8
48
*
602
Kela drug reimbursment
Children's severe malnutrition
8.9
47.8
64
74
N06AX16
ATC
venlafaxine; oral
8.9
46.9
63
73
F93.89
ICD-10 Finland
Other childhood emotional disorders
88.5
46.3
52
6
N06AB06
ATC
sertraline; oral
7.0
46.3
77
115
F90.9
ICD-10 Finland
Hyperkinetic disorder, unspecified
18.5
46.1
39
21
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
5.6
45.7
97
185
ZYC01
NOMESCO Finland
Remote contact by phone
7.7
44.6
68
92
RT150, ,
NOMESCO Finland
74.0
44.4
51
7
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
9.0
43.8
58
66
G40.9
ICD-10 Finland
Epilepsy, unspecified
11.0
43.1
49
45
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
6.7
42.4
74
116
F81.8
ICD-10 Finland
Other developmental disorders of scholastic skills
116.2
42.2
46
*
RL140, ,
NOMESCO Finland
116.2
42.2
46
*
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
7.7
41.8
63
84
IGV01
NOMESCO Finland
Psychiatric network contact
147.6
41.2
44
*
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
18.7
40.4
34
18
A28
ICPC
Limited function/disability NOS
6.3
39.9
73
120
N06AB10
ATC
escitalopram; oral
4.2
39.4
124
326
RS222, ,
NOMESCO Finland
17.7
39.4
34
19
Z87.6
ICD-10 Finland
Personal history of certain conditions arising in the perinatal period
6.5
39.2
69
109
3154A
ICD-9 Finland
Specific delays in development, Coördination disorder
+∞
39.1
38
*
ZXE00
NOMESCO Finland
One hour or less
3.0
38.8
286
1286
Z01.8
ICD-10 Finland
Other specified special examinations
3.6
37.4
157
504
F80.8
ICD-10 Finland
Other developmental disorders of speech and language
102.7
37.2
41
*
EBA15
NOMESCO Finland
Extraction of multiple teeth
10.5
36.8
43
41
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
7.0
36.1
59
86
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
10.5
36.0
42
40
RL130, ,
NOMESCO Finland
68.3
35.4
41
6
Z31.5
ICD-10 Finland
Genetic counselling
4.5
35.3
96
225
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
184.0
35.2
37
*
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
4.1
34.2
109
288
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
33.9
228
962
Z63.7
ICD-10 Finland
Other stressful life events affecting family and household
5.4
33.4
72
138
331
Kela drug reimbursment
Atomoxetine, dexamphetamine, guanfacine and lisdexamphetamine
13.6
33.4
33
24
N05BA04
ATC
oxazepam; oral
4.9
32.8
80
171
F84.9
ICD-10 Finland
Pervasive developmental disorder, unspecified
323.1
32.4
33
*
F98.8
ICD-10 Finland
Other specified behavioural and emotional disorders with onset usually occurring in childhood and adolescence
89.4
32.2
36
*
N05AH02
ATC
clozapine; systemic
+∞
31.8
31
*
F98.00
ICD-10 Finland
Nonorganic enuresis nocturna
13.8
31.7
31
22
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.9
31.7
110
308
XX4AW, ,
NOMESCO Finland
9.1
31.6
41
45
R1260
NOMESCO Finland
Evaluation of communicative skills
40.0
31.5
40
10
F81.9
ICD-10 Finland
Developmental disorder of scholastic skills, unspecified
61.3
31.5
37
6
P74
ICPC
Anxiety disorder/anxiety state
6.1
31.4
59
99
F93.9
ICD-10 Finland
Childhood emotional disorder, unspecified
+∞
30.8
30
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.3
30.1
137
458
XF400
NOMESCO Finland
ECG with 12 standard connections
3.2
30.0
143
491
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.2
29.9
66
129
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
297.0
29.3
30
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
8.5
29.3
40
47
F84.5
ICD-10 Finland
Asperger syndrome
81.6
29.2
33
*
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
11.7
28.7
31
26
F20.9
ICD-10 Finland
Schizophrenia, unspecified
+∞
28.7
28
*
IFA99
NOMESCO Finland
Other psychiatric pharmacotherapy service
+∞
28.7
28
*
H01AC01
ATC
somatropin; parenteral
6.6
28.5
49
75
ZXY51
NOMESCO Finland
2-person team, doctor-nurse
65.1
28.4
33
5
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.1
28.4
145
518
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
+∞
27.7
27
*
RS220, ,
NOMESCO Finland
10.5
27.6
32
30
R1250
NOMESCO Finland
Evaluation of functional capability
30.6
27.5
37
12
K03.66
ICD-10 Finland
Tooth plaque
3.0
27.4
147
539
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
42.0
27.2
34
8
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
28.3
27.0
37
13
ICB02
NOMESCO Finland
Psychiatric treatment plan, extended/prolonged
+∞
26.6
26
*
N03AX14
ATC
levetiracetam; systemic
7.3
26.4
41
56
P99
ICPC
Psychological disorders other
9.8
26.4
32
32
AA1AD
NOMESCO Finland
CT of head and brain
4.1
26.3
81
207
R1410
NOMESCO Finland
Drawing up a rehabilitation plan
94.9
26.1
29
*
F88
ICD-10 Finland
Other disorders of psychological development
94.9
26.1
29
*
P85
ICPC
Mental retardation
50.8
25.7
31
6
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
3.8
25.4
86
235
WX408
NOMESCO Finland
General anesthesy, balanced
2.6
25.4
204
921
IEV99
NOMESCO Finland
Other psychiatric network intervention
71.3
25.3
29
*
N05AA02
ATC
levomepromazine; systemic
132.0
25.1
27
*
ZXA00
NOMESCO Finland
Right side
3.3
24.5
105
335
N06AX11
ATC
mirtazapine; oral
3.3
24.0
102
324
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.8
23.8
148
585
P07.2
ICD-10 Finland
Extreme immaturity
54.8
23.5
28
5
F84.8
ICD-10 Finland
Other pervasive developmental disorders
233.6
23.2
24
*
WX882
NOMESCO Finland
High dependency care
3.5
23.0
87
256
H52.2
ICD-10 Finland
Astigmatism
4.8
22.5
54
113
ZXY82
NOMESCO Finland
Nurse in multidisciplinary team
+∞
22.5
22
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
9.4
22.5
28
29
N05CD08
ATC
midazolam; nasal, systemic
6.2
22.3
40
64
F40.1
ICD-10 Finland
Social phobias
7.5
22.1
33
43
R5140
NOMESCO Finland
Monitoring the use of the aid
7.3
22.1
34
46
N05BA01
ATC
diazepam; systemic, rectal
4.8
21.9
52
108
RD210, ,
NOMESCO Finland
4.3
21.7
60
141
F92.9
ICD-10 Finland
Mixed disorder of conduct and emotions, unspecified
213.4
21.2
22
*
R11
ICD-10 Finland
Nausea and vomiting
3.2
21.1
96
317
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.9
21.0
113
411
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.4
21.0
56
128
FM2CE, ,
NOMESCO Finland
3.7
20.5
70
192
IBZ06
NOMESCO Finland
Evaluation concerning developmental neuropsychiatry
+∞
20.4
20
*
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
+∞
20.4
20
*
WX002
NOMESCO Finland
Sedation and analgesia
3.6
20.2
74
213
P72
ICPC
Schizophrenia
203.3
20.2
21
*
ICB06, ,
NOMESCO Finland
203.3
20.2
21
*
P27.1
ICD-10 Finland
Bronchopulmonary dysplasia originating in the perinatal period
40.6
20.0
25
6
IEP99
NOMESCO Finland
Other psychiatric family intervention
31.7
19.7
26
8
C03CA01
ATC
furosemide; systemic
5.1
19.7
43
83
RF120, ,
NOMESCO Finland
26.4
19.5
27
10
N06AX12
ATC
bupropion; oral
5.2
19.5
42
80
OAA43, ,
SPAT
3.6
19.5
69
194
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.4
19.4
165
752
N05BA09
ATC
clobazam; oral
18.4
19.4
30
16
183
Kela drug reimbursment
Lamotrigin and topiramate
34.8
19.3
25
7
H50.31
ICD-10 Finland
Intermittent exotropia
6.5
19.3
33
50
ZXE40
NOMESCO Finland
More than seven and less than nine hours
6.5
19.3
33
50
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.3
19.2
52
120
N06AB04
ATC
citalopram; systemic
5.3
19.2
40
74
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
38.9
19.0
24
6
ZXA10
NOMESCO Finland
Bilateral
2.8
19.0
114
438
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
5.4
19.0
39
71
F39
ICD-10 Finland
Unspecified mood [affective] disorder
21.1
19.0
28
13
IBA02
NOMESCO Finland
Evaluation of need for psychiatric rehabilitation
8.7
18.9
25
28
SPAT1240
SPAT
Therapeutic discussion
3.1
18.7
90
306
JF1AB
NOMESCO Finland
Passage examination of small bowell with X-ray
22.0
18.5
27
12
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.4
18.5
71
210
ZXA05
NOMESCO Finland
Left side
3.0
18.5
90
308
F54
ICD-10 Finland
Psychological and behavioural factors associated with disorders or diseases classified elsewhere
+∞
18.4
18
*
F92.8
ICD-10 Finland
Other mixed disorders of conduct and emotions
+∞
18.4
18
*
J45.1
ICD-10 Finland
Nonallergic asthma
3.0
18.3
92
321
Z71.8
ICD-10 Finland
Other specified counselling
2.2
18.3
243
1332
WX730
NOMESCO Finland
Conventional respirator
27.0
18.2
25
9
RT490, ,
NOMESCO Finland
96.7
18.2
20
*
F98.2
ICD-10 Finland
Feeding disorder of infancy and childhood
183.4
18.2
19
*
IEP03
NOMESCO Finland
Focused parental counselling
6.5
18.1
31
47
H50.30
ICD-10 Finland
Intermittent esotropy
6.9
18.1
29
41
KFH00
NOMESCO Finland
Operation for undescended or ectopic testis
8.1
17.9
25
30
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
6.1
17.8
32
51
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.6
17.8
35
61
F41.1
ICD-10 Finland
Generalized anxiety disorder
4.3
17.7
48
111
C07AA05
ATC
propranolol; systemic
2.9
17.6
91
322
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
50.8
17.5
21
*
F43.1
ICD-10 Finland
Post-traumatic stress disorder
7.8
17.4
25
31
H50.0
ICD-10 Finland
Convergent concomitant strabismus
6.2
17.4
31
49
SPAT1307
SPAT
Psychosocial counselling and guidance
2.9
17.4
90
319
TPH07
NOMESCO Finland
Cathetrisation of artery
3.2
17.2
75
240
Z07
ICPC
Education problem
5.9
17.2
32
53
WX722
NOMESCO Finland
PEEP
5.3
17.1
36
67
ZXD20
NOMESCO Finland
Day surgery
3.2
17.0
73
232
Q53.1
ICD-10 Finland
Undescended testicle, unilateral
6.4
16.9
29
44
P76
ICPC
Depressive disorder
4.2
16.9
48
115
P22.0
ICD-10 Finland
Respiratory distress syndrome of newborn
18.1
16.8
26
14
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
3.8
16.7
53
138
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
3.1
16.6
74
240
301
Kela drug reimbursment
Growth hormone
7.8
16.6
24
30
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.2
16.6
71
225
G47.3
ICD-10 Finland
Sleep apnoea
3.6
16.5
58
162
SPAT1389
SPAT
Visit based on need for special support
2.9
16.4
88
317
T90
ICPC
Diabetes non-insulin dependent
4.7
16.4
39
81
F89
ICD-10 Finland
Unspecified disorder of psychological development
61.1
16.3
19
*
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
+∞
16.3
16
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.3
16.3
66
202
R62.8
ICD-10 Finland
Other lack of expected normal physiological development
7.5
16.2
24
31
IEY01
NOMESCO Finland
Psychoeducation, individual
163.5
16.1
17
*
P29
ICPC
Psychological sympt/compl other
2.9
16.1
86
309
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.9
16.1
82
287
N03AF02
ATC
oxcarbazepine; oral
4.9
16.0
37
75
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
19.4
15.9
24
12
RF210, ,
NOMESCO Finland
7.7
15.8
23
29
ZXD05
NOMESCO Finland
Urgent procedure
2.3
15.8
147
691
P24
ICPC
Specific learning problem
4.0
15.7
47
117
SPAT1243
SPAT
Psychiatric/psychological examination
4.3
15.7
42
96
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.4
15.7
132
594
F59
ICD-10 Finland
Unspecified behavioural syndromes associated with physiological disturbances and physical factors
+∞
15.3
15
*
IER04
NOMESCO Finland
Rehabilitative psychiatric group intervention, functional
+∞
15.3
15
*
N06AX21
ATC
duloxetine; oral
5.4
15.2
31
56
N03AX16
ATC
[U] pregabalin
4.1
15.1
43
103
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
5.2
15.1
32
60
K59.09
ICD-10 Finland
Constipation, unspecified
3.7
15.1
50
134
E66.01
ICD-10 Finland
Obesity due to excess calories
3.2
15.0
65
207
Z03.2
ICD-10 Finland
Observation for suspected mental and behavioural disorders
13.3
15.0
26
19
N05BA06
ATC
lorazepam; systemic, sublingual
36.7
15.0
19
5
RS211, ,
NOMESCO Finland
14.3
14.9
25
17
AA5HE
NOMESCO Finland
Brain ultrasound examination in a child
3.9
14.9
45
113
Q99.8
ICD-10 Finland
Other specified chromosome abnormalities
27.6
14.8
20
7
H53.0
ICD-10 Finland
Amblyopia ex anopsia
4.7
14.6
35
73
XKD00
NOMESCO Finland
Uroflowmetry
4.6
14.6
36
77
Q87.88
ICD-10 Finland
Other specified congenital malformation syndromes, not elsewhere classified
30.5
14.4
19
6
SPAT1234
SPAT
Support of social functional capacity
12.1
14.4
26
21
H66.0
ICD-10 Finland
Acute suppurative otitis media
2.0
14.3
217
1227
IER02
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, group
+∞
14.3
14
*
F84.0
ICD-10 Finland
Childhood autism
+∞
14.3
14
*
F70.1
ICD-10 Finland
Mild mental retardation, Significant impairment of behaviour requiring attention or treatment
+∞
14.3
14
*
F25.9
ICD-10 Finland
Schizoaffective disorder, unspecified
+∞
14.3
14
*
F99
ICD-10 Finland
Mental disorder, not otherwise specified
24.1
14.3
20
8
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
76.9
14.2
16
*
L28
ICPC
Limited function/disability (L)
3.5
14.2
52
149
R4190
NOMESCO Finland
Nutritional therapy
2.6
14.2
88
342
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
6.5
14.2
24
36
F98.02
ICD-10 Finland
Non-organic nocturnal and diurnal enuresis
143.8
14.1
15
*
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
143.8
14.1
15
*
DFF20
NOMESCO Finland
Audiometry for children
5.9
14.0
26
43
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
4.4
13.9
36
80
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
6.3
13.8
24
37
101
Kela drug reimbursment
Anterior pituitary hypofunction
5.6
13.8
27
47
A11CC03
ATC
alfacalcidol; systemic
6.9
13.7
22
31
SPAT1229
SPAT
Assessment of need for aid
11.6
13.6
25
21
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.5
13.5
50
144
RS140, ,
NOMESCO Finland
51.2
13.5
16
*
ZX114
NOMESCO Finland
Intramuscular
6.6
13.3
22
32
XCK00
NOMESCO Finland
Perimetry
6.6
13.3
22
32
F41.09
ICD-10 Finland
UNS Panic Syndrome
6.6
13.3
22
32
N05AN01
ATC
lithium; oral
+∞
13.3
13
*
F93.80
ICD-10 Finland
Generalized anxiety in the bardom age
+∞
13.3
13
*
DFF00
NOMESCO Finland
Pure tone audiometry
3.8
13.2
41
105
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
4.9
13.2
30
60
ZYB04
NOMESCO Finland
Outreach service in patient’s home or everyday environment
134.0
13.1
14
*
RT130, ,
NOMESCO Finland
134.0
13.1
14
*
SPAT1396
SPAT
Meeting with multidisciplinary group of experts
4.7
13.1
31
64
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.5
13.1
47
133
F41.8
ICD-10 Finland
Other specified anxiety disorders
4.6
13.1
32
68
N06BA09
ATC
atomoxetine; oral
24.8
13.0
18
7
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
3.3
12.8
52
159
ZY000
NOMESCO Finland
Hospital inpatient
14.5
12.7
21
14
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
4.3
12.6
34
78
F40.2
ICD-10 Finland
Specific (isolated) phobias
27.2
12.6
17
6
L02AE02
ATC
leuprorelin; implant, parenteral
10.6
12.6
24
22
RS312, ,
NOMESCO Finland
47.9
12.5
15
*
Q89.7
ICD-10 Finland
Multiple congenital malformations, not elsewhere classified
47.9
12.5
15
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
21.7
12.5
18
8
SPAT1365
SPAT
Health check-up performed during first study year due to special need in students of upper secondary schools or vocational schools
9.7
12.5
25
25
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
4.1
12.5
35
83
H03AA01
ATC
levothyroxine sodium; systemic
2.9
12.5
62
214
WX402
NOMESCO Finland
General anaesthesia
2.0
12.4
158
833
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.0
12.3
173
943
Z63.8
ICD-10 Finland
Other specified problems related to primary support group
66.9
12.3
14
*
RT420, ,
NOMESCO Finland
+∞
12.2
12
*
3153A
ICD-9 Finland
Specific delays in development, Developmental speech or language disorder[KIELENKEHITYKSEN ERITYISVAIKEUS]
+∞
12.2
12
*
RT422, ,
NOMESCO Finland
+∞
12.2
12
*
G80.2
ICD-10 Finland
Spastic hemiplegic cerebral palsy
30.7
12.2
16
5
IER01
NOMESCO Finland
Psychoeducation, group
30.7
12.2
16
5
F91.9
ICD-10 Finland
Conduct disorder, unspecified
124.3
12.1
13
*
IBB01
NOMESCO Finland
Psychiatric functioning capacity evaluation
124.3
12.1
13
*
IBB02
NOMESCO Finland
Psychiatric evaluation of working capacity and rehabilitation
124.3
12.1
13
*
SPAT1262
SPAT
Handing over of treatment supplies
3.0
12.1
55
180
P03
ICPC
Feeling depressed
2.4
12.1
97
424
E34.39
ICD-10 Finland
Short stature, not elsewhere classified
4.8
12.0
28
57
C07AB07
ATC
bisoprolol; oral
2.7
12.0
67
246
N06AX26
ATC
vortioxetine; oral
3.6
11.9
40
108
H35.1
ICD-10 Finland
Retinopathy of prematurity
36.0
11.9
15
*
P01
ICPC
Feeling anxious/nervous/tense
2.0
11.8
156
832
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
25.6
11.7
16
6
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
25.6
11.7
16
6
RF420, ,
NOMESCO Finland
17.3
11.7
18
10
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
10.6
11.6
22
20
J45.9
ICD-10 Finland
Asthma, unspecified
2.2
11.5
109
511
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.8
11.4
26
52
KA1MN
NOMESCO Finland
Glomerular filtration rate (GFR) Isotope mesurement
4.2
11.4
31
72
G80.1
ICD-10 Finland
Spastic diplegic cerebral palsy
28.8
11.3
15
5
W0A12
NOMESCO Finland
Planned therapy visit for psychiatric disease
28.8
11.3
15
5
G80.9
ICD-10 Finland
Cerebral palsy, unspecified
62.1
11.3
13
*
N05AB03
ATC
perphenazine; systemic, rectal
62.1
11.3
13
*
IBA03
NOMESCO Finland
Psychotherapy evaluation
62.1
11.3
13
*
RS120, ,
NOMESCO Finland
21.9
11.2
16
7
NE1AA
NOMESCO Finland
Pelvis X-ray examination
4.9
11.2
25
49
X78
ICD-10 Finland
Intentional self-harm by sharp object
+∞
11.2
11
*
N05AE05
ATC
lurasidone; oral
+∞
11.2
11
*
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
+∞
11.2
11
*
F31.6
ICD-10 Finland
Bipolar affective disorder, current episode mixed
+∞
11.2
11
*
IAB01
NOMESCO Finland
Psychiatric pharmacotherapy consultation
+∞
11.2
11
*
F90.1
ICD-10 Finland
Hyperkinetic conduct disorder
114.5
11.2
12
*
ZXY80
NOMESCO Finland
Doctor in multidisciplinary team
114.5
11.2
12
*
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
5.0
11.0
24
46
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
3.5
10.9
39
110
EMB30
NOMESCO Finland
Adenotomy
2.1
10.9
121
603
K08.3
ICD-10 Finland
Retained dental root
4.9
10.8
24
47
F43.22
ICD-10 Finland
Adaptation disorder with mixed anxiety and depression
4.0
10.8
31
75
201
Kela drug reimbursment
Chronic cardiac insufficiency
5.8
10.8
20
33
WX892
NOMESCO Finland
Monitored bed care
2.9
10.7
53
182
SPAT1281
SPAT
Other administrative function
2.6
10.7
64
243
J21.0
ICD-10 Finland
Acute bronchiolitis due to respiratory syncytial virus
3.6
10.7
37
102
SPAT1297
SPAT
Other function in accordance with speech therapy nomenclature
5.0
10.6
23
44
XG413
NOMESCO Finland
Spirometry with oscillometry
4.0
10.6
31
76
Z02.7
ICD-10 Finland
Issue of medical certificate
2.9
10.5
50
168
TJD20
NOMESCO Finland
Change of gastrostomy tube
14.9
10.5
17
11
R4140
NOMESCO Finland
Psychotherapy
57.2
10.4
12
*
F98.9
ICD-10 Finland
Unspecified behavioural and emotional disorders with onset usually occurring in childhood and adolescence
57.2
10.4
12
*
ZXY60
NOMESCO Finland
2-person team, nurses
57.2
10.4
12
*
IAZ98
NOMESCO Finland
Other internal psychiatric consultation
57.2
10.4
12
*
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
57.2
10.4
12
*
N05AF03
ATC
chlorprothixene; systemic
57.2
10.4
12
*
N06BA12
ATC
lisdexamfetamine; oral
8.5
10.3
22
25
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
8.5
10.3
22
25
WYA50
NOMESCO Finland
Student oral health check consistent with decree to assess need for oral health guidance and services
0.4
10.3
65
1270
F20
ICD-10 Finland
Schizophrenia
+∞
10.2
10
*
ZXY52
NOMESCO Finland
2-person team, doctor-psychologist
+∞
10.2
10
*
P98
ICPC
Psychosis NOS/other
104.8
10.2
11
*
P07.01
ICD-10 Finland
Extremely low birth weight 500-749 g
104.8
10.2
11
*
F20.30
ICD-10 Finland
Undifferentiated schizophrenia continuous
104.8
10.2
11
*
F91.3
ICD-10 Finland
Oppositional defiant disorder
104.8
10.2
11
*
A10BA02
ATC
metformin; oral
3.1
10.2
43
135
TAB00
NOMESCO Finland
Lumbar puncture
3.5
10.2
36
101
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.5
10.2
36
101
A06AC01
ATC
ispaghula (psylla seeds); oral
2.7
10.1
55
199
XF404
NOMESCO Finland
Ambulatory ECG
3.1
10.0
43
136
E66.8
ICD-10 Finland
Other obesity
4.2
10.0
27
62
127
Kela drug reimbursment
Transplant complication
5.2
10.0
21
39
C03DA01
ATC
spironolactone; oral
3.7
9.9
32
84
R51.80
ICD-10 Finland
Headache
2.0
9.9
124
644
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
7.9
9.9
22
27
IGY02, ,
SPAT
10.2
9.9
19
18
K00.40
ICD-10 Finland
Postnatal enamel hypoplasia
2.9
9.8
48
164
T82
ICPC
Obesity
4.3
9.8
26
59
TJD00
NOMESCO Finland
Insertion of nasogastric or naso-gastroduodenal tube
5.5
9.7
19
33
RS311, ,
NOMESCO Finland
38.1
9.7
12
*
ZX120
NOMESCO Finland
Intravenous
2.7
9.7
54
198
N05CF01
ATC
zopiclone; oral
3.1
9.7
41
129
F80.0
ICD-10 Finland
Specific speech articulation disorder
8.8
9.6
20
22
XF600
NOMESCO Finland
Bloodpressure measurement
2.3
9.6
74
317
Z29
ICPC
Social problem NOS
4.6
9.6
23
48
F43.9
ICD-10 Finland
Reaction to severe stress, unspecified
5.2
9.6
20
37
Q38.1
ICD-10 Finland
Ankyloglossia
3.9
9.6
29
73
F33.4
ICD-10 Finland
Recurrent depressive disorder, currently in remission
16.0
9.5
15
9
N28
ICPC
Limited function/disability (N)
16.0
9.5
15
9
F42.1
ICD-10 Finland
Predominantly compulsive acts [obsessional rituals]
24.8
9.5
13
5
N88
ICPC
Epilepsy
11.7
9.5
17
14
Z04.4
ICD-10 Finland
Examination and observation following alleged rape and seduction
19.1
9.5
14
7
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.6
9.5
32
87
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
2.1
9.4
107
536
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
3.3
9.4
37
111
P07.3
ICD-10 Finland
Other preterm infants
3.1
9.4
40
126
H66.9
ICD-10 Finland
Otitis media, unspecified
1.8
9.4
165
958
F93.1
ICD-10 Finland
Phobic anxiety disorder of childhood
52.4
9.4
11
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.0
9.4
109
551
Q53.2
ICD-10 Finland
Undescended testicle, bilateral
12.8
9.3
16
12
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.0
9.3
117
608
K07.24
ICD-10 Finland
Open bite
3.2
9.3
38
117
QA4S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in face
10.9
9.2
17
15
F95.2
ICD-10 Finland
Combined vocal and multiple motor tic disorder [de la Tourette]
95.1
9.2
10
*
F92.0
ICD-10 Finland
Depressive conduct disorder
95.1
9.2
10
*
Z63.5
ICD-10 Finland
Disruption of family by separation and divorce
95.1
9.2
10
*
ICC01
NOMESCO Finland
Psychiatric treatment plan, transfer to psychiatric outpatient clinic
95.1
9.2
10
*
RS231, ,
NOMESCO Finland
95.1
9.2
10
*
F50.0
ICD-10 Finland
Anorexia nervosa
+∞
9.2
9
*
AA400
NOMESCO Finland
Electroconvulsive therapy
+∞
9.2
9
*
ZXY49
NOMESCO Finland
Other health care provider
+∞
9.2
9
*
F19.29
ICD-10 Finland
Addiction caused by several drugs in combination and by other psychoactive substances UNS
+∞
9.2
9
*
F70.9
ICD-10 Finland
Mild mental retardation, Without mention of impairment of behaviour
+∞
9.2
9
*
XA820, ,
NOMESCO Finland
+∞
9.2
9
*
ZX108
NOMESCO Finland
Inhalation
8.0
9.2
20
24
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
2.7
9.2
51
187
G40.89
ICD-10 Finland
Other epilepsy
28.6
9.1
12
*
RT190, ,
NOMESCO Finland
28.6
9.1
12
*
G91.1
ICD-10 Finland
Obstructive hydrocephalus
28.6
9.1
12
*
BF20A, ,
NOMESCO Finland
20.7
9.1
13
6
IEP02
NOMESCO Finland
Child-centred family therapy
4.0
9.0
26
63
N03AX11
ATC
topiramate; oral
7.2
9.0
21
28
H52.0
ICD-10 Finland
Hypermetropia
2.9
9.0
42
140
EJC20
NOMESCO Finland
Operation on frenulum of tongue
4.4
8.9
23
51
205
Kela drug reimbursment
Chronic hypertension
4.4
8.9
23
51
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
4.4
8.9
23
51
C08CA01
ATC
amlodipine; oral
3.0
8.9
40
130
F50.9
ICD-10 Finland
Eating disorder, unspecified
10.2
8.9
17
16
R32
ICD-10 Finland
Unspecified urinary incontinence
10.2
8.9
17
16
E34.35
ICD-10 Finland
Abnormal growth retardation
3.4
8.9
32
91
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
3.0
8.8
41
136
UKC02
NOMESCO Finland
Cystoscopy
3.6
8.8
30
82
C07AB02
ATC
metoprolol; systemic
3.5
8.8
31
87
R5130
NOMESCO Finland
Repair work or maintenance done on the aid
11.0
8.7
16
14
TLC00
NOMESCO Finland
Insertion of intrauterine device
3.8
8.7
27
69
186
Kela drug reimbursment
Growth retardation associated with renal failure (growth hormone)
4.4
8.7
22
48
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
3.4
8.7
32
92
A03FA02
ATC
cisapride; oral, rectal
3.3
8.7
33
97
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.5
8.7
30
83
IEP01
NOMESCO Finland
Psychoeducation, family
17.7
8.6
13
7
N03AX12
ATC
[U] gabapentin; oral
3.7
8.6
28
74
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
6.8
8.6
21
30
R13
ICD-10 Finland
Dysphagia
4.2
8.5
23
53
H81
ICPC
Excessive ear wax
2.4
8.5
62
259
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
8.5
81
379
XG410
NOMESCO Finland
Flow-volume spirometry
3.4
8.5
31
89
R27.0
ICD-10 Finland
Ataxia, unspecified
47.5
8.4
10
*
F81.1
ICD-10 Finland
Specific spelling disorder
47.5
8.4
10
*
P07.02
ICD-10 Finland
Extremely low birth weight 750-999 g
47.5
8.4
10
*
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
8.2
8.4
18
21
ZX199
NOMESCO Finland
Other rote
8.2
8.4
18
21
SPAT1395
SPAT
Health check-up of persons outside student and working life
13.4
8.4
14
10
P22
ICPC
Child behaviour symptom/complaint
2.7
8.4
47
173
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.4
8.4
30
85
SPAT1292
SPAT
Other function in accordance with SHToL (Finnish classification of nursing interventions)
3.6
8.3
28
76
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.2
8.3
22
50
R2110
NOMESCO Finland
Giving the first information
3.6
8.2
27
72
FDE00
NOMESCO Finland
Closure of patent ductus arteriosus
85.5
8.2
9
*
F94.8
ICD-10 Finland
Other childhood disorders of social functioning
85.5
8.2
9
*
G80.0
ICD-10 Finland
Spastic quadriplegic cerebral palsy
85.5
8.2
9
*
IAA02
NOMESCO Finland
Consultation concerning further psychiatric treatment
85.5
8.2
9
*
N05AD01
ATC
haloperidol; systemic
85.5
8.2
9
*
Q04.8
ICD-10 Finland
Other specified congenital malformations of brain
85.5
8.2
9
*
H50.1
ICD-10 Finland
Divergent concomitant strabismus
8.6
8.2
17
19
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
+∞
8.1
8
*
F33.30
ICD-10 Finland
Recurrent depression, severe episode without somatic syndrome
+∞
8.1
8
*
IAB08
NOMESCO Finland
Consultation concerning a patient who has attempted suicide
+∞
8.1
8
*
F28
ICD-10 Finland
Other nonorganic psychotic disorders
+∞
8.1
8
*
F25.10
ICD-10 Finland
Schizoaffective syndrome, depressive type with only concomitant bipolar and schizophrenic symptoms
+∞
8.1
8
*
IDR03
NOMESCO Finland
Systematic group therapy, dialectical behaviour therapy (DBT)
+∞
8.1
8
*
Z35.7
ICD-10 Finland
Supervision of high-risk pregnancy due to social problems
+∞
8.1
8
*
IDY04
NOMESCO Finland
Systematic individual therapy, dialectical behaviour therapy (DBT)
+∞
8.1
8
*
N05AE04
ATC
ziprasidone; systemic
+∞
8.1
8
*
X84
ICD-10 Finland
Intentional self-harm by unspecified means
+∞
8.1
8
*
3159X
ICD-9 Finland
Specific delays in development, Unspecified delay in development
+∞
8.1
8
*
RT250, ,
NOMESCO Finland
+∞
8.1
8
*
OAB43, ,
SPAT
0.5
8.1
114
1713
K05.10
ICD-10 Finland
Gingivitis (chronic) NOS
1.8
8.1
151
889
H65.3
ICD-10 Finland
Chronic mucoid otitis media
2.1
8.1
78
367
F33.00
ICD-10 Finland
Recurrent depression, mild episode without somatic syndrome
12.2
8.1
14
11
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.5
8.0
28
78
S18
ICPC
Laceration/cut
1.7
8.0
208
1343
NF1DA
NOMESCO Finland
X-ray of hips
10.3
8.0
15
14
E34.31
ICD-10 Finland
Short stature, prenatal disorder
8.2
8.0
17
20
UGC02
NOMESCO Finland
Rigid bronchoscopy
8.2
8.0
17
20
F32.8
ICD-10 Finland
Other depressive episodes
13.8
7.9
13
9
R4110, ,
SPAT
2.8
7.9
41
145
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
4.4
7.9
20
44
R62.9
ICD-10 Finland
Lack of expected normal physiological development, unspecified
31.7
7.8
10
*
A97
ICPC
No disease
1.7
7.8
173
1067
P81
ICPC
Hyperkinetic disorder
3.6
7.8
26
70
N03AX18
ATC
lacosamide; systemic
16.3
7.8
12
7
RS122, ,
NOMESCO Finland
16.3
7.8
12
7
J21.9
ICD-10 Finland
Acute bronchiolitis, unspecified
2.6
7.8
46
174
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
3.1
7.8
32
99
F34.1
ICD-10 Finland
Dysthymia
11.2
7.8
14
12
M41.4
ICD-10 Finland
Neuromuscular scoliosis
20.9
7.8
11
5
M03BX01
ATC
baclofen; systemic
20.9
7.8
11
5
RF430, ,
NOMESCO Finland
20.9
7.8
11
5
D09
ICPC
Nausea
2.1
7.7
77
367
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.5
7.7
26
71
H02AB09
ATC
hydrocortisone; systemic
2.9
7.6
36
121
R06.5
ICD-10 Finland
Mouth breathing
2.3
7.6
61
266
N03AE01
ATC
clonazepam; systemic
12.4
7.6
13
10
E22.80
ICD-10 Finland
Central precocious puberty
12.4
7.6
13
10
WX704
NOMESCO Finland
Intubation
2.7
7.6
42
154
F51.0
ICD-10 Finland
Nonorganic insomnia
2.1
7.5
72
337
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.1
7.5
71
331
SPAT1216
SPAT
Assessment of functional ability
2.5
7.5
47
183
Q93.5
ICD-10 Finland
Other deletions of part of a chromosome
42.7
7.5
9
*
A02BC02
ATC
pantoprazole; systemic
1.7
7.5
168
1039
RK220, ,
NOMESCO Finland
9.0
7.5
15
16
X44
ICD-10 Finland
Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological substances
9.0
7.5
15
16
H61.2
ICD-10 Finland
Impacted cerumen
2.8
7.5
38
133
F42.2
ICD-10 Finland
Mixed obsessional thoughts and acts
14.3
7.4
12
8
SPAT1245
SPAT
Provision of support and information to patient’s family members
4.2
7.4
20
46
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.0
7.4
81
400
H47.2
ICD-10 Finland
Optic atrophy
17.5
7.4
11
6
P07.10
ICD-10 Finland
Other low birth weight 1000-1499 g
23.8
7.3
10
*
RS314, ,
NOMESCO Finland
23.8
7.3
10
*
WW804
NOMESCO Finland
Transfer from treating institution to higher-Level care, accompanied by doctor
7.1
7.3
17
23
K06.19
ICD-10 Finland
Gingival hyperplasia UNS
11.3
7.3
13
11
OAB72, ,
SPAT
7.7
7.3
16
20
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
7.7
7.3
16
20
A41.9
ICD-10 Finland
Sepsis, unspecified
3.7
7.2
23
60
XX4BW, ,
NOMESCO Finland
9.6
7.2
14
14
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.4
7.2
15
17
ICZ04
NOMESCO Finland
Preparation of psychiatric treatment plan
75.9
7.2
8
*
ZXY81
NOMESCO Finland
Psychologist in multidisciplinary team
75.9
7.2
8
*
OAA46, ,
SPAT
3.4
7.2
26
74
J35.2
ICD-10 Finland
Hypertrophy of adenoids
2.0
7.2
80
397
R06.0
ICD-10 Finland
Dyspnoea
2.0
7.2
83
418
IEY15
NOMESCO Finland
Acute psychiatry, stabilising intervention
+∞
7.1
7
*
IBC98
NOMESCO Finland
Other child protection assessment
+∞
7.1
7
*
IBZ02
NOMESCO Finland
Somatic assessment of psychiatric patient
+∞
7.1
7
*
RT320, ,
NOMESCO Finland
+∞
7.1
7
*
N05AX15
ATC
cariprazine; oral
+∞
7.1
7
*
RT121, ,
NOMESCO Finland
+∞
7.1
7
*
RL710, ,
NOMESCO Finland
+∞
7.1
7
*
F31.0
ICD-10 Finland
Bipolar affective disorder, current episode hypomanic
+∞
7.1
7
*
F94.0
ICD-10 Finland
Elective mutism
+∞
7.1
7
*
3153X
ICD-9 Finland
Specific delays in development, Developmental speech or language disorder[PUHEEN KEHITYKSEN ERITYISVAIKEUS]
+∞
7.1
7
*
IER05
NOMESCO Finland
Rehabilitative psychiatric group intervention, social skills
+∞
7.1
7
*
ZXY58
NOMESCO Finland
2-person team, nurse-occupational therapist
+∞
7.1
7
*
ZXY03
NOMESCO Finland
Occupational therapist
+∞
7.1
7
*
G40.10
ICD-10 Finland
Simple partial seizures
12.7
7.1
12
9
WW500
NOMESCO Finland
Blood transfusion
3.4
7.1
25
70
KFH10
NOMESCO Finland
Orchiopexy
7.3
7.1
16
21
L17
ICPC
Foot/toe symptom/complaint
1.7
7.0
174
1102
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.9
7.0
93
490
XJC10
NOMESCO Finland
Oesophageal pH monitoring
10.3
7.0
13
12
N29
ICPC
Neurological sympt/complt other
8.0
7.0
15
18
Z50.1
ICD-10 Finland
Other physical therapy
4.1
7.0
19
44
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.6
7.0
41
155
ZXE50
NOMESCO Finland
More than nine and less than 12 hours
6.5
7.0
17
25
F10.09
ICD-10 Finland
Alcohol intoxication UNS
28.5
6.9
9
*
Z61.7
ICD-10 Finland
Personal frightening experience in childhood
28.5
6.9
9
*
P29.30
ICD-10 Finland
Delayed closure of the ductus arteriosus
19.0
6.9
10
5
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
19.0
6.9
10
5
J01EE02
ATC
sulfadiazine and trimethoprim; systemic
1.6
6.9
252
1755
JAB00
NOMESCO Finland
Division and ligature of inguinal hernia sac
3.1
6.9
28
86
K03.00
ICD-10 Finland
Approximal wear
2.4
6.9
48
197
B01AA03
ATC
warfarin; systemic
3.9
6.9
20
49
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
3.6
6.8
22
58
G40.19
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
11.4
6.8
12
10
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
4.1
6.8
19
45
E23.01
ICD-10 Finland
Isolated deficiency of growth hormone
4.1
6.8
19
45
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
4.2
6.8
18
41
TFC99
NOMESCO Finland
Catheterisation of heart with other procedure
4.4
6.8
17
37
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
1.9
6.8
89
468
P22.9
ICD-10 Finland
Respiratory distress of newborn, unspecified
5.8
6.7
18
30
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
6.7
6.7
16
23
FXA00
NOMESCO Finland
Total cardiopulmonary bypass in normothermia or moderate hypothermia at concurrent surgical procedure
2.8
6.7
33
114
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
3.1
6.7
28
88
Z51.80
ICD-10 Finland
Manipulation of puberty development with hormone therapy
13.1
6.6
11
8
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
7.2
6.6
15
20
GAE10
NOMESCO Finland
Closure of previous incision of chest wall
7.2
6.6
15
20
K92.0
ICD-10 Finland
Haematemesis
7.2
6.6
15
20
XQ800
NOMESCO Finland
Prick test
2.0
6.6
71
348
G81.1
ICD-10 Finland
Spastic hemiplegia
37.9
6.6
8
*
ZXY56
NOMESCO Finland
2-person team, nurse-psychologist
37.9
6.6
8
*
IAZ99
NOMESCO Finland
Other psychiatric consultation
37.9
6.6
8
*
T74.1
ICD-10 Finland
Physical abuse
4.3
6.6
17
38
U07
ICPC
Urine symptom/complaint other
2.8
6.6
33
115
K04.5
ICD-10 Finland
Chronic apical periodontitis
2.1
6.5
65
309
R4120, ,
SPAT
10.4
6.5
12
11
R63.8
ICD-10 Finland
Other symptoms and signs concerning food and fluid intake
15.8
6.5
10
6
F42.9
ICD-10 Finland
Obsessive-compulsive disorder, unspecified
15.8
6.5
10
6
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
15.8
6.5
10
6
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
3.5
6.5
22
60
AA1AA
NOMESCO Finland
Head X-ray examination
8.9
6.5
13
14
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.4
6.5
43
172
R55
ICD-10 Finland
Syncope and collapse
2.6
6.5
39
149
ZXY01
NOMESCO Finland
Chief Physician, Head of Department or Deputy Chief Physician
21.4
6.5
9
*
F50.1
ICD-10 Finland
Atypical anorexia nervosa
21.4
6.5
9
*
LC2AE
NOMESCO Finland
Ultrasound examination of uterus and parametria
2.7
6.4
34
122
A29
ICPC
General symptom/complaint other
2.0
6.4
68
332
NFK30
NOMESCO Finland
Angulation, rotation or displacement osteotomy of femur
11.6
6.3
11
9
SPAT1317
SPAT
Planned health check-up monitoring, health check-up performed based on individual need
1.5
6.3
255
1807
Z98.8
ICD-10 Finland
Other specified postsurgical states
5.6
6.3
17
29
285
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
9.5
6.3
12
12
R1240
NOMESCO Finland
Social assessment of need and possibilities of rehabilitation
9.5
6.3
12
12
SPAT1369
SPAT
Meeting with student welfare group of educational institution
5.2
6.3
18
33
F60.8
ICD-10 Finland
Other specific personality disorders
66.1
6.3
7
*
Q87.14
ICD-10 Finland
Noonan's syndrome
66.1
6.3
7
*
WX732
NOMESCO Finland
High frequency respirator
66.1
6.3
7
*
RS310, ,
NOMESCO Finland
66.1
6.3
7
*
T85.0
ICD-10 Finland
Mechanical complication of ventricular intracranial (communicating) shunt
66.1
6.3
7
*
WX290, ,
SPAT
2.9
6.2
28
92
W0A10
NOMESCO Finland
Mapping of psychosocial situation
13.6
6.2
10
7
BC00A, ,
NOMESCO Finland
13.6
6.2
10
7
H60.9
ICD-10 Finland
Otitis externa, unspecified
2.1
6.2
60
283
RS121, ,
NOMESCO Finland
5.9
6.2
16
26
D10
ICPC
Vomiting
1.9
6.1
84
447
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
3.5
6.1
21
58
IBZ98
NOMESCO Finland
Other psychiatric evaluation
+∞
6.1
6
*
F31.20
ICD-10 Finland
Bipolar disorder, manic episode with mood-congruent psychotic symptoms
+∞
6.1
6
*
IEY08
NOMESCO Finland
Psychiatric coaching, domestic and community skills
+∞
6.1
6
*
F31.1
ICD-10 Finland
Bipolar affective disorder, current episode manic without psychotic symptoms
+∞
6.1
6
*
G80.8
ICD-10 Finland
Other cerebral palsy
+∞
6.1
6
*
IAB07
NOMESCO Finland
Consultation concerning a patient with self-harm intention
+∞
6.1
6
*
F43.25
ICD-10 Finland
Adaptive disorder with mixed mental disorder and behavioral disorder
+∞
6.1
6
*
R44.0
ICD-10 Finland
Auditory hallucinations
+∞
6.1
6
*
F71.0
ICD-10 Finland
Moderate mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
6.1
6
*
IER03
NOMESCO Finland
Psychiatric disorder-specific group intervention
+∞
6.1
6
*
N05AX16
ATC
brexpiprazole; oral
+∞
6.1
6
*
RL720, ,
NOMESCO Finland
+∞
6.1
6
*
IEY03
NOMESCO Finland
Vocational rehabilitation
+∞
6.1
6
*
F64.9
ICD-10 Finland
Gender identity disorder, unspecified
+∞
6.1
6
*
R5120
NOMESCO Finland
Preparation of an aid
7.8
6.1
13
16
XCD10
NOMESCO Finland
Electrophysiological examination of eye
7.8
6.1
13
16
Q75.3
ICD-10 Finland
Macrocephaly
17.1
6.1
9
5
N03AX22
ATC
perampanel; oral
17.1
6.1
9
5
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
10.5
6.1
11
10
P19
ICPC
Drug abuse
10.5
6.1
11
10
G91.0
ICD-10 Finland
Communicating hydrocephalus
25.3
6.0
8
*
Q85.00
ICD-10 Finland
Neurofibromatosis, type 1
25.3
6.0
8
*
F90.8
ICD-10 Finland
Other hyperkinetic disorders
25.3
6.0
8
*
F19.1
ICD-10 Finland
Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances, harmful use
25.3
6.0
8
*
346
Kela drug reimbursment
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
8.8
6.0
12
13
A10BK03
ATC
empagliflozin; oral
8.8
6.0
12
13
31
HP
Congenital heart failure surgery
8.8
6.0
12
13
Q21.10
ICD-10 Finland
Persistent ostium secundum
3.1
6.0
25
78

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Paediatric neurology
421 [44777781]
2.2e+00
2.6e+00
2.9e+00
—
4.2e+00
3.2e+00
3.2e+00
cases:38.28%
controls:6.20%
cases:33.72%
controls:3.59%
cases:13.08%
controls:0.79%
—
—
cases:28.78%
controls:0.63%
cases:42.69%
controls:2.90%
cases:49.07%
controls:3.82%
129
193
208
2919
116
114
228
3058
45
25
299
3147
—
99
20
245
3150
146
91
196
3048
159
114
165
2867
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
1.9e+00
2.6e+00
—
1.0e+50
4.0e+00
2.9e+00
2.8e+00
cases:15.13%
controls:2.63%
cases:16.57%
controls:1.42%
—
—
cases:6.98%
controls:0.00%
cases:10.47%
controls:0.22%
cases:17.25%
controls:1.08%
cases:30.56%
controls:2.55%
51
82
286
3030
57
45
287
3127
—
24
0
320
3172
36
7
308
3163
59
34
283
3105
99
76
225
2905
Occupational therapy
R4120 [2001310234]
2.7e+00
3.2e+00
1.0e+50
1.0e+50
—
3.3e+00
3.0e+00
cases:4.45%
controls:0.32%
cases:5.81%
controls:0.25%
cases:2.03%
controls:0.00%
cases:2.03%
controls:0.00%
—
—
cases:6.73%
controls:0.25%
cases:7.72%
controls:0.40%
15
10
322
3102
20
8
324
3164
7
0
337
3172
7
0
337
3172
—
23
8
319
3131
25
12
299
2969
Outpatient Visit
OP [9202]
6.1e-01
8.9e-01
8.1e-01
5.3e+00
1.8e+00
1.1e+00
1.0e+00
cases:71.81%
controls:58.16%
cases:67.44%
controls:45.90%
cases:24.71%
controls:12.77%
cases:52.91%
controls:0.54%
cases:43.60%
controls:11.20%
cases:69.30%
controls:42.63%
cases:81.17%
controls:60.89%
242
1810
95
1302
232
1456
112
1716
85
405
259
2767
182
17
162
3155
150
355
194
2815
237
1338
105
1801
263
1815
61
1166
Neuropsychological evaluation of need and possibilities to rehabilitation
R1230 [2001310176]
2.6e+00
2.9e+00
—
—
1.0e+50
2.4e+00
3.5e+00
cases:2.08%
controls:0.16%
cases:3.20%
controls:0.19%
—
—
—
—
cases:1.74%
controls:0.00%
cases:3.80%
controls:0.35%
cases:8.33%
controls:0.27%
7
5
330
3107
11
6
333
3166
—
—
6
0
338
3170
13
11
329
3128
27
8
297
2973
Physiotherapist
Z3226 [2001311560]
1.4e+00
2.1e+00
2.1e+00
1.0e+50
—
2.7e+00
2.2e+00
cases:14.54%
controls:4.21%
cases:7.27%
controls:0.95%
cases:1.74%
controls:0.22%
cases:4.07%
controls:0.00%
—
—
cases:8.48%
controls:0.64%
cases:9.26%
controls:1.14%
49
131
288
2981
25
30
319
3142
6
7
338
3165
14
0
330
3172
—
29
20
313
3119
30
34
294
2947
Physiotherapy
R4110 [2001310233]
1.2e+00
1.8e+00
2.5e+00
1.0e+50
—
2.1e+00
1.8e+00
cases:11.57%
controls:3.63%
cases:6.98%
controls:1.23%
cases:2.33%
controls:0.19%
cases:1.45%
controls:0.00%
—
—
cases:9.65%
controls:1.31%
cases:12.35%
controls:2.25%
39
113
298
2999
24
39
320
3133
8
6
336
3166
5
0
339
3172
—
33
41
309
3098
40
67
284
2914
Social worker
Z2446 [2001311559]
1.3e+00
2.2e+00
—
—
—
2.4e+00
3.5e+00
cases:8.61%
controls:2.47%
cases:3.20%
controls:0.38%
—
—
—
—
—
—
cases:2.34%
controls:0.22%
cases:6.48%
controls:0.20%
29
77
308
3035
11
12
333
3160
—
—
—
8
7
334
3132
21
6
303
2975
Psychologist
Z2445 [2001311558]
2.2e+00
3.3e+00
1.0e+50
1.0e+50
—
3.4e+00
—
cases:5.93%
controls:0.67%
cases:4.94%
controls:0.19%
cases:3.20%
controls:0.00%
cases:2.33%
controls:0.00%
—
—
cases:4.39%
controls:0.16%
—
—
20
21
317
3091
17
6
327
3166
11
0
333
3172
8
0
336
3172
—
15
5
327
3134
—
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
2.5e+00
—
—
—
—
2.9e+00
2.6e+00
cases:5.64%
controls:0.48%
—
—
—
—
—
—
—
—
cases:3.51%
controls:0.19%
cases:5.86%
controls:0.47%
19
15
318
3097
—
—
—
—
12
6
330
3133
19
14
305
2967
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
1.6e+00
2.3e+00
—
—
—
2.1e+00
2.0e+00
cases:5.04%
controls:1.06%
cases:4.36%
controls:0.47%
—
—
—
—
—
—
cases:3.51%
controls:0.45%
cases:9.88%
controls:1.41%
17
33
320
3079
15
15
329
3157
—
—
—
12
14
330
3125
32
42
292
2939
Counselling and guidance which enhance independent living
R2130 [2001310196]
1.6e+00
2.3e+00
—
1.0e+50
—
2.1e+00
1.9e+00
cases:7.42%
controls:1.61%
cases:4.36%
controls:0.47%
—
—
cases:1.45%
controls:0.00%
—
—
cases:4.97%
controls:0.64%
cases:11.42%
controls:1.81%
25
50
312
3062
15
15
329
3157
—
5
0
339
3172
—
17
20
325
3119
37
54
287
2927
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
2.7e+00
—
—
—
—
2.1e+00
3.0e+00
cases:3.26%
controls:0.22%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.22%
cases:4.01%
controls:0.20%
11
7
326
3105
—
—
—
—
6
7
336
3132
13
6
311
2975
Disturbance of activity and attention
F90.0 [45542870]
—
—
—
1.0e+50
—
4.4e+00
3.0e+00
—
—
—
—
—
—
cases:10.17%
controls:0.00%
—
—
cases:11.40%
controls:0.16%
cases:15.43%
controls:0.87%
—
—
—
35
0
309
3172
—
39
5
303
3134
50
26
274
2955
oxcarbazepine; oral
N03AF02 [21604418]
2.5e+00
2.2e+00
—
—
—
2.6e+00
—
cases:3.26%
controls:0.29%
cases:2.03%
controls:0.22%
—
—
—
—
—
—
cases:2.05%
controls:0.16%
—
—
11
9
326
3103
7
7
337
3165
—
—
—
7
5
335
3134
—
Functional capacity evaluation
443351003 [40481051]
1.8e+00
2.1e+00
—
—
—
2.8e+00
1.0e+00
cases:3.56%
controls:0.58%
cases:1.74%
controls:0.22%
—
—
—
—
—
—
cases:2.63%
controls:0.16%
cases:1.54%
controls:0.57%
12
18
325
3094
6
7
338
3165
—
—
—
9
5
333
3134
5
17
319
2964
Physical Medicine And Rehabilitation
25 [38004468]
1.2e+00
2.2e+00
1.0e+50
—
—
2.2e+00
1.1e+00
cases:5.64%
controls:1.77%
cases:4.94%
controls:0.60%
cases:2.62%
controls:0.00%
—
—
—
—
cases:6.14%
controls:0.70%
cases:8.33%
controls:2.82%
19
55
318
3057
17
19
327
3153
9
0
335
3172
—
—
21
22
321
3117
27
84
297
2897
Delayed milestone
R62.0 [45597195]
2.7e+00
3.9e+00
1.0e+50
1.0e+50
—
—
—
cases:11.28%
controls:0.84%
cases:7.27%
controls:0.16%
cases:1.45%
controls:0.00%
cases:1.74%
controls:0.00%
—
—
—
—
—
—
38
26
299
3086
25
5
319
3167
5
0
339
3172
6
0
338
3172
—
—
—
Other specified special examinations
Z01.8 [45581003]
1.3e+00
2.2e+00
—
—
—
1.7e+00
9.7e-01
cases:8.01%
controls:2.22%
cases:5.23%
controls:0.60%
—
—
—
—
—
—
cases:5.85%
controls:1.08%
cases:7.72%
controls:3.09%
27
69
310
3043
18
19
326
3153
—
—
—
20
34
322
3105
25
92
299
2889
Measurement of bone age from hand and elbow using X-ray
NK6MA [2001308495]
1.1e+00
9.2e-01
—
—
—
2.5e+00
2.4e+00
cases:4.45%
controls:1.54%
cases:2.03%
controls:0.82%
—
—
—
—
—
—
cases:2.34%
controls:0.19%
cases:4.94%
controls:0.47%
15
48
322
3064
7
26
337
3146
—
—
—
8
6
334
3133
16
14
308
2967
Medical doctor
Z2221 [2001311556]
1.2e+00
1.3e+00
—
—
—
1.7e+00
1.8e+00
cases:9.50%
controls:3.12%
cases:4.36%
controls:1.20%
—
—
—
—
—
—
cases:4.97%
controls:0.96%
cases:9.26%
controls:1.68%
32
97
305
3015
15
38
329
3134
—
—
—
17
30
325
3109
30
50
294
2931
Audiology
64 [38004489]
1.4e+00
1.4e+00
1.4e+00
1.0e+50
—
1.4e+00
1.6e+00
cases:7.42%
controls:1.93%
cases:4.65%
controls:1.17%
cases:1.45%
controls:0.35%
cases:1.45%
controls:0.00%
—
—
cases:4.68%
controls:1.18%
cases:8.95%
controls:1.91%
25
60
312
3052
16
37
328
3135
5
11
339
3161
5
0
339
3172
—
16
37
326
3102
29
57
295
2924
Speech therapy
Z50.5 [45547321]
1.8e+00
1.8e+00
—
—
—
2.2e+00
1.5e+00
cases:4.15%
controls:0.74%
cases:2.33%
controls:0.38%
—
—
—
—
—
—
cases:3.22%
controls:0.38%
cases:2.47%
controls:0.57%
14
23
323
3089
8
12
336
3160
—
—
—
11
12
331
3127
8
17
316
2964
somatropin; parenteral
H01AC01 [21602690]
1.6e+00
1.4e+00
1.9e+00
—
—
1.3e+00
1.3e+00
cases:2.97%
controls:0.61%
cases:3.20%
controls:0.82%
cases:1.45%
controls:0.22%
—
—
—
—
cases:3.51%
controls:0.99%
cases:4.32%
controls:1.17%
10
19
327
3093
11
26
333
3146
5
7
339
3165
—
—
12
31
330
3108
14
35
310
2946
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
1.5e+00
1.6e+00
—
—
—
2.4e+00
1.7e+00
cases:4.45%
controls:1.06%
cases:1.45%
controls:0.28%
—
—
—
—
—
—
cases:1.75%
controls:0.16%
cases:3.09%
controls:0.57%
15
33
322
3079
5
9
339
3163
—
—
—
6
5
336
3134
10
17
314
2964
Pediatric Medicine
37 [38004477]
2.5e-01
2.8e-01
-1.0e-01
3.8e+00
8.8e-01
4.5e-01
4.3e-01
cases:56.08%
controls:49.74%
cases:37.21%
controls:31.02%
cases:8.43%
controls:9.24%
cases:13.37%
controls:0.35%
cases:15.99%
controls:7.32%
cases:36.84%
controls:27.01%
cases:46.60%
controls:36.16%
189
1548
148
1564
128
984
216
2188
29
293
315
2879
46
11
298
3161
55
232
289
2938
126
848
216
2291
151
1078
173
1903
Nonallergic asthma
J45.1 [45557625]
8.1e-01
9.4e-01
1.7e+00
—
1.8e+00
9.8e-01
8.6e-01
cases:7.12%
controls:3.31%
cases:4.94%
controls:1.99%
cases:1.74%
controls:0.32%
—
—
cases:2.62%
controls:0.44%
cases:5.26%
controls:2.04%
cases:6.79%
controls:2.99%
24
103
313
3009
17
63
327
3109
6
10
338
3162
—
9
14
335
3156
18
64
324
3075
22
89
302
2892
Speech therapy
R4130 [2001310235]
2.7e+00
—
—
—
—
—
2.6e+00
cases:3.86%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:0.37%
13
8
324
3104
—
—
—
—
—
15
11
309
2970
Examination of ears and hearing
Z01.1 [45547279]
7.4e-01
1.8e+00
—
—
-1.0e+50
1.7e+00
9.8e-01
cases:8.01%
controls:3.98%
cases:5.23%
controls:0.95%
—
—
—
—
cases:0.00%
controls:0.16%
cases:4.09%
controls:0.80%
cases:6.17%
controls:2.42%
27
124
310
2988
18
30
326
3142
—
—
0
5
344
3165
14
25
328
3114
20
72
304
2909
More than one and less than three hours
ZXE10 [2001311401]
8.7e-01
1.0e+00
—
—
—
2.5e+00
1.5e+00
cases:12.17%
controls:5.46%
cases:3.78%
controls:1.39%
—
—
—
—
—
—
cases:5.85%
controls:0.51%
cases:7.10%
controls:1.64%
41
170
296
2942
13
44
331
3128
—
—
—
20
16
322
3123
23
49
301
2932
General evaluation of the need for rehabilitation
R1100 [2001310172]
2.3e+00
—
—
—
—
—
2.4e+00
cases:3.26%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
cases:4.01%
controls:0.37%
11
11
326
3101
—
—
—
—
—
13
11
311
2970
Inpatient Hospital
21 [8717]
5.5e-01
7.1e-01
9.0e-01
1.0e+50
1.8e+00
1.1e+00
5.5e-01
cases:42.43%
controls:29.85%
cases:15.99%
controls:8.54%
cases:3.20%
controls:1.32%
cases:6.40%
controls:0.00%
cases:5.23%
controls:0.95%
cases:16.08%
controls:6.05%
cases:25.93%
controls:16.81%
143
929
194
2183
55
271
289
2901
11
42
333
3130
22
0
322
3172
18
30
326
3140
55
190
287
2949
84
501
240
2480
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
9.3e-01
1.3e+00
—
—
—
1.5e+00
1.9e+00
cases:4.75%
controls:1.93%
cases:3.20%
controls:0.88%
—
—
—
—
—
—
cases:3.22%
controls:0.76%
cases:4.94%
controls:0.81%
16
60
321
3052
11
28
333
3144
—
—
—
11
24
331
3115
16
24
308
2957
Amblyopia ex anopsia
H53.0 [45581704]
2.1e+00
—
—
—
—
2.4e+00
—
cases:2.37%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.19%
—
—
8
9
329
3103
—
—
—
—
7
6
335
3133
—
calcium (different salts in combination); oral
A12AA20 [21600872]
1.4e+00
2.2e+00
—
—
—
2.2e+00
1.4e+00
cases:1.48%
controls:0.39%
cases:1.74%
controls:0.19%
—
—
—
—
—
—
cases:1.75%
controls:0.19%
cases:2.16%
controls:0.54%
5
12
332
3100
6
6
338
3166
—
—
—
6
6
336
3133
7
16
317
2965
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
8.3e-01
1.5e+00
—
—
—
2.2e+00
1.4e+00
cases:8.01%
controls:3.66%
cases:2.03%
controls:0.47%
—
—
—
—
—
—
cases:2.92%
controls:0.32%
cases:3.40%
controls:0.87%
27
114
310
2998
7
15
337
3157
—
—
—
10
10
332
3129
11
26
313
2955
Other therapy enhancing rehabilitation
R4160 [2001310240]
2.5e+00
—
—
—
—
—
1.9e+00
cases:2.67%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.37%
9
7
328
3105
—
—
—
—
—
8
11
316
2970
Scheduled procedure
ZXD10 [2001311387]
7.0e-01
2.5e-01
—
—
—
1.9e+00
1.7e+00
cases:16.91%
controls:9.16%
cases:4.07%
controls:3.18%
—
—
—
—
—
—
cases:6.14%
controls:0.96%
cases:8.02%
controls:1.58%
57
285
280
2827
14
101
330
3071
—
—
—
21
30
321
3109
26
47
298
2934
Case Management Agency
251B00000X [38004193]
-6.9e-02
-9.7e-03
4.9e-01
3.2e+00
6.1e-01
3.2e-02
1.3e-01
cases:38.87%
controls:40.52%
cases:34.30%
controls:34.52%
cases:20.93%
controls:13.93%
cases:14.53%
controls:0.69%
cases:23.26%
controls:14.10%
cases:36.84%
controls:36.09%
cases:46.60%
controls:43.48%
131
1261
206
1851
118
1095
226
2077
72
442
272
2730
50
22
294
3150
80
447
264
2723
126
1133
216
2006
151
1296
173
1685
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
1.8e+00
—
—
—
—
—
2.4e+00
cases:4.75%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.17%
16
26
321
3086
—
—
—
—
—
6
5
318
2976
spironolactone; oral
C03DA01 [21601534]
1.7e+00
2.4e+00
—
—
—
—
—
cases:2.67%
controls:0.48%
cases:2.03%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
9
15
328
3097
7
6
337
3166
—
—
—
—
—
Other healthcare associate professional
Z3229 [2001311561]
1.4e+00
1.3e+00
—
—
—
2.6e+00
6.6e-01
cases:5.64%
controls:1.51%
cases:1.45%
controls:0.41%
—
—
—
—
—
—
cases:2.05%
controls:0.16%
cases:1.54%
controls:0.81%
19
47
318
3065
5
13
339
3159
—
—
—
7
5
335
3134
5
24
319
2957
Day surgery
ZXD20 [2001311388]
1.6e+00
—
—
—
—
2.4e+00
—
cases:3.56%
controls:0.77%
—
—
—
—
—
—
—
—
cases:2.34%
controls:0.22%
—
—
12
24
325
3088
—
—
—
—
8
7
334
3132
—
Retinol [Moles/volume] in Serum or Plasma
14905-4 [3013005]
1.6e+00
1.4e+00
—
—
—
—
2.2e+00
cases:2.97%
controls:0.61%
cases:1.45%
controls:0.38%
—
—
—
—
—
—
—
—
cases:3.09%
controls:0.34%
10
19
327
3093
5
12
339
3160
—
—
—
—
10
10
314
2971
Neurology
13 [38004458]
1.2e+00
1.5e+00
—
—
—
2.0e+00
1.8e+00
cases:2.37%
controls:0.71%
cases:1.74%
controls:0.38%
—
—
—
—
—
—
cases:2.63%
controls:0.38%
cases:6.48%
controls:1.14%
8
22
329
3090
6
12
338
3160
—
—
—
9
12
333
3127
21
34
303
2947
Psychiatry
26 [38004469]
1.0e+50
—
—
1.0e+50
1.0e+50
1.0e+50
3.6e+00
cases:1.78%
controls:0.00%
—
—
—
—
cases:2.91%
controls:0.00%
cases:2.03%
controls:0.00%
cases:2.63%
controls:0.00%
cases:8.95%
controls:0.27%
6
0
331
3112
—
—
10
0
334
3172
7
0
337
3170
9
0
333
3139
29
8
295
2973
Thorax X-ray examination
GD1AA [2001303617]
7.5e-01
6.0e-01
—
—
—
1.6e+00
1.3e+00
cases:8.61%
controls:4.24%
cases:3.78%
controls:2.11%
—
—
—
—
—
—
cases:3.80%
controls:0.83%
cases:6.48%
controls:1.88%
29
132
308
2980
13
67
331
3105
—
—
—
13
26
329
3113
21
56
303
2925
Neuropsychological investigation
XA800 [2001300412]
—
—
1.0e+50
1.0e+50
—
—
3.6e+00
—
—
—
—
cases:2.91%
controls:0.00%
cases:1.45%
controls:0.00%
—
—
—
—
cases:9.57%
controls:0.30%
—
—
10
0
334
3172
5
0
339
3172
—
—
31
9
293
2972
salmeterol and fluticasone
R03AK06 [21603280]
8.8e-01
1.2e+00
1.1e+00
—
—
1.3e+00
9.2e-01
cases:2.67%
controls:1.12%
cases:3.78%
controls:1.17%
cases:1.45%
controls:0.47%
—
—
—
—
cases:4.68%
controls:1.27%
cases:5.86%
controls:2.42%
9
35
328
3077
13
37
331
3135
5
15
339
3157
—
—
16
40
326
3099
19
72
305
2909
One hour or less
ZXE00 [2001311394]
5.5e-01
4.6e-01
—
—
—
1.5e+00
1.4e+00
cases:17.51%
controls:10.93%
cases:5.81%
controls:3.75%
—
—
—
—
—
—
cases:6.43%
controls:1.50%
cases:10.49%
controls:2.82%
59
340
278
2772
20
119
324
3053
—
—
—
22
47
320
3092
34
84
290
2897
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
6.2e-01
1.1e+00
1.3e+00
—
1.2e+00
1.2e+00
1.2e+00
cases:6.82%
controls:3.79%
cases:6.10%
controls:2.11%
cases:2.03%
controls:0.54%
—
—
cases:2.03%
controls:0.60%
cases:4.97%
controls:1.59%
cases:7.10%
controls:2.35%
23
118
314
2994
21
67
323
3105
7
17
337
3155
—
7
19
337
3151
17
50
325
3089
23
70
301
2911
Left side
ZXA05 [2001311347]
1.5e+00
—
—
—
—
—
1.8e+00
cases:4.75%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.40%
16
34
321
3078
—
—
—
—
—
8
12
316
2969
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
1.4e+00
1.2e+00
—
—
—
1.9e+00
—
cases:5.64%
controls:1.51%
cases:2.33%
controls:0.69%
—
—
—
—
—
—
cases:2.34%
controls:0.35%
—
—
19
47
318
3065
8
22
336
3150
—
—
—
8
11
334
3128
—
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
4.1e-01
5.9e-01
9.7e-01
—
1.2e+00
1.0e+00
8.9e-01
cases:13.06%
controls:9.09%
cases:9.88%
controls:5.74%
cases:3.49%
controls:1.36%
—
—
cases:4.07%
controls:1.26%
cases:9.65%
controls:3.63%
cases:17.28%
controls:7.92%
44
283
293
2829
34
182
310
2990
12
43
332
3129
—
14
40
330
3130
33
114
309
3025
56
236
268
2745
Inpatient Visit
IP [9201]
2.9e-01
4.4e-01
—
1.0e+50
—
1.4e+00
1.6e+00
cases:5.64%
controls:4.27%
cases:2.62%
controls:1.70%
—
—
cases:2.62%
controls:0.00%
—
—
cases:4.68%
controls:1.15%
cases:7.41%
controls:1.61%
19
133
318
2979
9
54
335
3118
—
9
0
335
3172
—
16
36
326
3103
24
48
300
2933
Otolaryngology
4 [38004449]
4.9e-01
6.4e-01
6.9e-01
—
4.3e-01
1.1e+00
7.8e-01
cases:26.41%
controls:18.06%
cases:10.76%
controls:5.99%
cases:1.74%
controls:0.88%
—
—
cases:1.45%
controls:0.95%
cases:11.40%
controls:4.30%
cases:17.28%
controls:8.76%
89
562
248
2550
37
190
307
2982
6
28
338
3144
—
5
30
339
3140
39
135
303
3004
56
261
268
2720
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
5.7e-01
—
—
—
—
—
2.9e+00
cases:2.97%
controls:1.70%
—
—
—
—
—
—
—
—
—
—
cases:3.70%
controls:0.20%
10
53
327
3059
—
—
—
—
—
12
6
312
2975
Hyperkinetic disorder, unspecified
F90.9 [45533124]
—
1.0e+50
—
—
—
—
2.9e+00
—
—
cases:2.33%
controls:0.00%
—
—
—
—
—
—
—
—
cases:3.09%
controls:0.17%
—
8
0
336
3172
—
—
—
—
10
5
314
2976
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
5.7e-01
7.1e-01
1.4e+00
—
—
1.7e+00
1.2e+00
cases:4.45%
controls:2.57%
cases:2.91%
controls:1.45%
cases:1.45%
controls:0.35%
—
—
—
—
cases:4.39%
controls:0.86%
cases:6.79%
controls:2.11%
15
80
322
3032
10
46
334
3126
5
11
339
3161
—
—
15
27
327
3112
22
63
302
2918
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
5.0e-01
1.6e+00
—
—
—
1.4e+00
1.3e+00
cases:4.75%
controls:2.92%
cases:2.91%
controls:0.60%
—
—
—
—
—
—
cases:1.46%
controls:0.38%
cases:5.25%
controls:1.54%
16
91
321
3021
10
19
334
3153
—
—
—
5
12
337
3127
17
46
307
2935
Focused parental counselling
IEP03 [2001304195]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.20%
—
—
—
—
—
—
11
6
313
2975
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
4.1e-01
1.4e-01
2.2e+00
—
—
1.5e+00
1.4e+00
cases:3.86%
controls:2.60%
cases:1.45%
controls:1.26%
cases:1.45%
controls:0.16%
—
—
—
—
cases:2.92%
controls:0.70%
cases:3.70%
controls:0.94%
13
81
324
3031
5
40
339
3132
5
5
339
3167
—
—
10
22
332
3117
12
28
312
2953
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
3.0e-01
9.2e-01
1.2e+00
—
—
1.7e+00
1.2e+00
cases:3.26%
controls:2.44%
cases:3.78%
controls:1.54%
cases:1.45%
controls:0.44%
—
—
—
—
cases:4.68%
controls:0.92%
cases:6.79%
controls:2.18%
11
76
326
3036
13
49
331
3123
5
14
339
3158
—
—
16
29
326
3110
22
65
302
2916
Child behaviour symptom/complaint
P22 [2002000817]
1.2e+00
1.6e+00
—
—
—
1.0e+00
6.2e-01
cases:4.75%
controls:1.45%
cases:3.20%
controls:0.66%
—
—
—
—
—
—
cases:1.46%
controls:0.54%
cases:2.78%
controls:1.51%
16
45
321
3067
11
21
333
3151
—
—
—
5
17
337
3122
9
45
315
2936
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
1.2e+00
7.0e-01
—
—
—
—
1.6e+00
cases:5.34%
controls:1.70%
cases:1.45%
controls:0.73%
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.70%
18
53
319
3059
5
23
339
3149
—
—
—
—
11
21
313
2960
Pharmacy visit
OMOP4822462 [581458]
2.5e-01
3.0e-01
3.3e-01
1.3e+00
4.4e-01
4.2e-01
6.0e-01
cases:90.50%
controls:88.08%
cases:66.86%
controls:59.96%
cases:24.42%
controls:18.82%
cases:3.49%
controls:0.98%
cases:25.29%
controls:17.85%
cases:67.25%
controls:57.44%
cases:87.96%
controls:79.97%
305
2741
32
371
230
1902
114
1270
84
597
260
2575
12
31
332
3141
87
566
257
2604
230
1803
112
1336
285
2384
39
597
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
1.4e+00
—
—
—
—
2.2e+00
2.8e+00
cases:1.48%
controls:0.35%
—
—
—
—
—
—
—
—
cases:1.46%
controls:0.16%
cases:3.09%
controls:0.20%
5
11
332
3101
—
—
—
—
5
5
337
3134
10
6
314
2975
methylphenidate; oral
N06BA04 [21604757]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.19%
controls:0.74%
—
—
—
—
—
—
33
22
291
2959
Nutritional therapy
R4190 [2001310243]
7.1e-01
1.2e+00
-1.0e+50
—
—
1.3e+00
1.4e+00
cases:5.64%
controls:2.86%
cases:3.49%
controls:1.07%
cases:0.00%
controls:0.28%
—
—
—
—
cases:3.80%
controls:1.02%
cases:5.25%
controls:1.38%
19
89
318
3023
12
34
332
3138
0
9
344
3163
—
—
13
32
329
3107
17
41
307
2940
Office Visit
OMOP4822458 [581477]
5.0e-01
2.2e-01
5.5e-01
—
1.3e+00
8.1e-01
5.8e-01
cases:17.51%
controls:11.44%
cases:7.27%
controls:5.93%
cases:1.74%
controls:1.01%
—
—
cases:4.36%
controls:1.20%
cases:11.99%
controls:5.73%
cases:17.90%
controls:10.84%
59
356
278
2756
25
188
319
2984
6
32
338
3140
—
15
38
329
3132
41
180
301
2959
58
323
266
2658
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
1.4e+00
—
—
—
—
—
2.7e+00
cases:2.37%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.17%
8
18
329
3094
—
—
—
—
—
8
5
316
2976
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
1.6e-01
4.3e-01
—
—
—
1.4e+00
1.3e+00
cases:9.50%
controls:8.19%
cases:5.52%
controls:3.66%
—
—
—
—
—
—
cases:4.97%
controls:1.31%
cases:7.10%
controls:1.98%
32
255
305
2857
19
116
325
3056
—
—
—
17
41
325
3098
23
59
301
2922
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
7.7e-01
—
—
—
—
—
2.6e+00
cases:1.78%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.20%
6
26
331
3086
—
—
—
—
—
9
6
315
2975
Cathetrisation of vein
TPH04 [2001309597]
1.1e+00
—
—
—
—
1.9e+00
1.6e+00
cases:5.34%
controls:1.93%
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.25%
cases:4.63%
controls:1.01%
18
60
319
3052
—
—
—
—
6
8
336
3131
15
30
309
2951
Visit based on need for special support
SPAT1389 [2001700489]
9.0e-01
—
—
—
—
—
2.6e+00
cases:3.86%
controls:1.61%
—
—
—
—
—
—
—
—
—
—
cases:3.09%
controls:0.23%
13
50
324
3062
—
—
—
—
—
10
7
314
2974
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
4.9e-01
2.7e-01
1.5e+00
—
—
1.2e+00
1.3e+00
cases:8.01%
controls:5.08%
cases:3.20%
controls:2.46%
cases:1.74%
controls:0.41%
—
—
—
—
cases:4.09%
controls:1.21%
cases:6.79%
controls:1.88%
27
158
310
2954
11
78
333
3094
6
13
338
3159
—
—
14
38
328
3101
22
56
302
2925
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.8e-01
1.2e+00
—
—
—
1.7e+00
8.4e-01
cases:2.37%
controls:1.80%
cases:2.91%
controls:0.91%
—
—
—
—
—
—
cases:3.80%
controls:0.70%
cases:7.72%
controls:3.49%
8
56
329
3056
10
29
334
3143
—
—
—
13
22
329
3117
25
104
299
2877
Pediatric Surgery
OMOP4822020 [45756819]
6.7e-01
4.8e-01
1.3e+00
—
—
9.8e-01
8.8e-01
cases:21.36%
controls:12.18%
cases:9.30%
controls:5.99%
cases:2.33%
controls:0.66%
—
—
—
—
cases:11.11%
controls:4.46%
cases:18.52%
controls:8.59%
72
379
265
2733
32
190
312
2982
8
21
336
3151
—
—
38
140
304
2999
60
256
264
2725
Outpatient Hospital
22 [8756]
6.6e-01
3.9e-01
—
—
1.1e+00
1.0e+00
7.6e-01
cases:35.61%
controls:22.30%
cases:9.88%
controls:6.94%
—
—
—
—
cases:2.91%
controls:1.01%
cases:11.11%
controls:4.24%
cases:19.14%
controls:9.96%
120
694
217
2418
34
220
310
2952
—
—
10
32
334
3138
38
133
304
3006
62
297
262
2684
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
1.7e-01
4.6e-01
1.2e+00
—
—
1.2e+00
1.2e+00
cases:10.09%
controls:8.64%
cases:6.10%
controls:3.94%
cases:2.03%
controls:0.63%
—
—
—
—
cases:5.56%
controls:1.75%
cases:7.10%
controls:2.18%
34
269
303
2843
21
125
323
3047
7
20
337
3152
—
—
19
55
323
3084
23
65
301
2916
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
6.9e-01
1.7e-01
—
—
—
1.0e+00
7.1e-01
cases:10.39%
controls:5.49%
cases:4.36%
controls:3.72%
—
—
—
—
—
—
cases:7.02%
controls:2.64%
cases:12.65%
controls:6.64%
35
171
302
2941
15
118
329
3054
—
—
—
24
83
318
3056
41
198
283
2783
Epistaxis
R04.0 [45606791]
2.4e+00
—
—
—
—
-1.0e+50
—
cases:1.78%
controls:0.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
6
5
331
3107
—
—
—
—
0
6
342
3133
—
Sleep apnoea
G47.3 [45562094]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.17%
—
—
—
—
—
—
6
5
318
2976
CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood
14135-8 [3001405]
9.2e-01
—
—
—
—
—
2.4e+00
cases:2.08%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.20%
7
26
330
3086
—
—
—
—
—
7
6
317
2975
CD3+CD8+ (T8 suppressor) cells/cells in Blood
8101-8 [3007449]
9.2e-01
—
—
—
—
—
2.4e+00
cases:2.08%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.20%
7
26
330
3086
—
—
—
—
—
7
6
317
2975
CD3 cells/Lymphocytes in Blood
90304-7 [1175426]
7.8e-01
—
—
—
—
—
2.4e+00
cases:2.08%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.23%
7
30
330
3082
—
—
—
—
—
8
7
316
2974
CD3 cells [#/volume] in Blood
8122-4 [3011412]
7.8e-01
—
—
—
—
—
2.4e+00
cases:2.08%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.23%
7
30
330
3082
—
—
—
—
—
8
7
316
2974
Inhibin B [Mass/volume] in Serum or Plasma
34319-4 [3045781]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.23%
—
—
—
—
—
—
8
7
316
2974
CD3-CD16+CD56+ (Natural killer) cells/cells in Blood
8112-5 [3027831]
7.8e-01
—
—
—
—
—
2.4e+00
cases:2.08%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.23%
7
30
330
3082
—
—
—
—
—
8
7
316
2974
Undescended testicle, unilateral
Q53.1 [45597134]
1.0e+00
2.1e+00
—
—
—
2.4e+00
—
cases:2.08%
controls:0.74%
cases:1.45%
controls:0.19%
—
—
—
—
—
—
cases:2.34%
controls:0.22%
—
—
7
23
330
3089
5
6
339
3166
—
—
—
8
7
334
3132
—
pH of Capillary blood
2745-8 [3009343]
1.7e-01
4.6e-01
1.2e+00
—
—
1.2e+00
1.2e+00
cases:10.09%
controls:8.64%
cases:6.10%
controls:3.94%
cases:2.03%
controls:0.63%
—
—
—
—
cases:5.56%
controls:1.75%
cases:7.10%
controls:2.31%
34
269
303
2843
21
125
323
3047
7
20
337
3152
—
—
19
55
323
3084
23
69
301
2912
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
1.3e-01
3.7e-01
1.2e+00
—
—
1.1e+00
1.2e+00
cases:9.50%
controls:8.45%
cases:5.52%
controls:3.88%
cases:2.03%
controls:0.63%
—
—
—
—
cases:4.97%
controls:1.66%
cases:7.10%
controls:2.25%
32
263
305
2849
19
123
325
3049
7
20
337
3152
—
—
17
52
325
3087
23
67
301
2914
Gas panel - Capillary blood
24337-8 [3022313]
2.0e-01
3.7e-01
—
—
—
1.1e+00
1.3e+00
cases:9.79%
controls:8.19%
cases:5.23%
controls:3.66%
—
—
—
—
—
—
cases:4.09%
controls:1.43%
cases:5.86%
controls:1.74%
33
255
304
2857
18
116
326
3056
—
—
—
14
45
328
3094
19
52
305
2929
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
1.7e-01
5.1e-01
1.2e+00
—
—
1.2e+00
1.1e+00
cases:10.09%
controls:8.64%
cases:6.40%
controls:3.94%
cases:2.03%
controls:0.63%
—
—
—
—
cases:5.56%
controls:1.75%
cases:7.10%
controls:2.42%
34
269
303
2843
22
125
322
3047
7
20
337
3152
—
—
19
55
323
3084
23
72
301
2909
Asthma, unspecified
J45.9 [45562456]
9.1e-01
1.4e+00
—
—
—
1.1e+00
8.8e-01
cases:5.34%
controls:2.22%
cases:3.49%
controls:0.88%
—
—
—
—
—
—
cases:2.05%
controls:0.70%
cases:3.70%
controls:1.58%
18
69
319
3043
12
28
332
3144
—
—
—
7
22
335
3117
12
47
312
2934
budesonide; inhalant
R03BA02 [21603285]
1.1e+00
1.2e+00
—
—
—
8.5e-01
5.4e-01
cases:5.93%
controls:1.99%
cases:4.07%
controls:1.29%
—
—
—
—
—
—
cases:3.22%
controls:1.40%
cases:5.25%
controls:3.12%
20
62
317
3050
14
41
330
3131
—
—
—
11
44
331
3095
17
93
307
2888
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
2.7e-01
7.1e-01
1.4e+00
—
—
1.1e+00
1.2e+00
cases:10.68%
controls:8.39%
cases:7.56%
controls:3.88%
cases:2.03%
controls:0.50%
—
—
—
—
cases:6.43%
controls:2.20%
cases:12.65%
controls:4.36%
36
261
301
2851
26
123
318
3049
7
16
337
3156
—
—
22
69
320
3070
41
130
283
2851
Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood
80721-4 [21493690]
7.8e-01
—
—
—
—
—
2.2e+00
cases:2.08%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.27%
7
30
330
3082
—
—
—
—
—
8
8
316
2973
Psychiatric monitoring contact
IGY02 [2001304322]
1.5e+00
—
—
—
—
—
2.2e+00
cases:1.78%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.27%
6
13
331
3099
—
—
—
—
—
8
8
316
2973
sildenafil; oral
G04BE03 [21602648]
2.2e+00
—
—
—
—
—
1.9e+00
cases:1.78%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:1.54%
controls:0.23%
6
6
331
3106
—
—
—
—
—
5
7
319
2974
CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood
9728-7 [3025271]
9.2e-01
—
—
—
—
—
2.2e+00
cases:2.08%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.23%
7
26
330
3086
—
—
—
—
—
7
7
317
2974
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
8.8e-01
—
—
—
—
—
2.2e+00
cases:2.08%
controls:0.87%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.23%
7
27
330
3085
—
—
—
—
—
7
7
317
2974
CD3-CD19+ cells/cells in Blood
15196-9 [3006245]
8.5e-01
—
—
—
—
—
2.2e+00
cases:2.37%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.23%
8
32
329
3080
—
—
—
—
—
7
7
317
2974
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.20%
—
—
—
—
—
—
6
6
318
2975
Dehydroepiandrosterone sulfate (DHEA-S) [Moles/volume] in Serum or Plasma
14688-6 [3016616]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.20%
—
—
—
—
—
—
6
6
318
2975
More than three and less than five hours
ZXE20 [2001311408]
6.5e-01
—
—
—
—
—
2.2e+00
cases:4.45%
controls:2.38%
—
—
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.40%
15
74
322
3038
—
—
—
—
—
11
12
313
2969
Epilepsy and comparable convulsive disorders
111 [2001600111]
2.2e+00
—
—
—
—
—
—
cases:2.97%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
10
11
327
3101
—
—
—
—
—
—
Ankyloglossia
Q38.1 [45597124]
2.1e+00
—
—
—
—
—
—
cases:2.67%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
9
10
328
3102
—
—
—
—
—
—
budesonide; oral, sublingual
A07EA06 [21600658]
2.1e+00
—
—
—
—
—
—
cases:2.37%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
8
9
329
3103
—
—
—
—
—
—
Bile acid [Moles/volume] in Serum --fasting
35562-8 [3034274]
8.4e-01
—
—
—
—
—
2.1e+00
cases:1.48%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.30%
5
20
332
3092
—
—
—
—
—
8
9
316
2972
Wrist symptom/complaint
L11 [2002000635]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.30%
—
—
—
—
—
—
8
9
316
2972
Other specified prophylactic measures
Z29.8 [45537623]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.30%
—
—
—
—
—
—
8
9
316
2972
Planned health check-up monitoring, health check-up performed based on individual need
SPAT1317 [2001700418]
3.1e-01
-7.3e-02
—
—
—
1.1e+00
1.0e+00
cases:16.62%
controls:12.76%
cases:2.91%
controls:3.12%
—
—
—
—
—
—
cases:5.26%
controls:1.85%
cases:8.64%
controls:3.25%
56
397
281
2715
10
99
334
3073
—
—
—
18
58
324
3081
28
97
296
2884
midazolam; nasal, oral, parenteral, sublingual
N05CD08 [21604643]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.27%
—
—
—
—
—
—
7
8
317
2973
Ophthalmology
18 [38004463]
5.3e-01
6.7e-01
8.8e-01
—
9.4e-01
8.4e-01
5.8e-01
cases:16.62%
controls:10.54%
cases:11.92%
controls:6.46%
cases:2.03%
controls:0.85%
—
—
cases:2.62%
controls:1.04%
cases:13.45%
controls:6.28%
cases:21.30%
controls:13.18%
56
328
281
2784
41
205
303
2967
7
27
337
3145
—
9
33
335
3137
46
197
296
2942
69
393
255
2588
Sepsis, unspecified
A41.9 [45585911]
2.1e+00
—
—
—
—
—
—
cases:1.78%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
331
3105
—
—
—
—
—
—
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.23%
—
—
—
—
—
—
6
7
318
2974
High dependency care
WX882 [2001310847]
6.6e-01
1.1e+00
—
—
—
—
2.1e+00
cases:5.04%
controls:2.67%
cases:2.03%
controls:0.66%
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.23%
17
83
320
3029
7
21
337
3151
—
—
—
—
6
7
318
2974
B lymphocytes [#/volume] in Blood
11130-2 [3000060]
8.8e-01
—
—
—
—
—
2.1e+00
cases:2.37%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.23%
8
31
329
3081
—
—
—
—
—
6
7
318
2974
Amino acids [Identifier] in Serum or Plasma
12468-5 [3013336]
2.1e+00
—
—
—
—
—
—
cases:2.97%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
10
12
327
3100
—
—
—
—
—
—
Obesity due to excess calories
E66.01 [2000501501]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.09%
controls:0.40%
—
—
—
—
—
—
10
12
314
2969
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.4e-01
3.6e-01
4.6e-01
—
1.3e+00
1.0e+00
1.0e+00
cases:12.17%
controls:10.70%
cases:8.14%
controls:5.83%
cases:1.74%
controls:1.10%
—
—
cases:2.62%
controls:0.76%
cases:7.60%
controls:2.87%
cases:11.73%
controls:4.56%
41
333
296
2779
28
185
316
2987
6
35
338
3137
—
9
24
335
3146
26
90
316
3049
38
136
286
2845
Genetic counselling
Z31.5 [45590715]
1.7e-01
1.3e+00
—
—
—
2.0e+00
1.9e+00
cases:3.56%
controls:3.02%
cases:1.74%
controls:0.50%
—
—
—
—
—
—
cases:2.34%
controls:0.32%
cases:1.54%
controls:0.23%
12
94
325
3018
6
16
338
3156
—
—
—
8
10
334
3129
5
7
319
2974
cromoglicic acid; nasal
R01AC01 [21605033]
2.0e+00
—
—
—
—
—
—
cases:2.08%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
330
3103
—
—
—
—
—
—
Hospital outpatient
ZY010 [2001311599]
2.0e+00
—
—
—
—
—
—
cases:3.86%
controls:0.55%
—
—
—
—
—
—
—
—
—
—
—
—
13
17
324
3095
—
—
—
—
—
—
Observation for suspected nervous system disorder
Z03.3 [45609903]
1.2e+00
2.0e+00
—
—
—
—
—
cases:2.97%
controls:0.93%
cases:2.03%
controls:0.28%
—
—
—
—
—
—
—
—
—
—
10
29
327
3083
7
9
337
3163
—
—
—
—
—
Procedure duration 90 to 119 minutes
ZXE13 [2001311404]
9.9e-01
—
—
—
—
2.0e+00
—
cases:2.97%
controls:1.12%
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.29%
—
—
10
35
327
3077
—
—
—
—
7
9
335
3130
—
Glomerular filtration rate (GFR) Isotope mesurement
KA1MN [2001305637]
1.2e-01
—
—
—
—
2.0e+00
1.3e+00
cases:1.48%
controls:1.32%
—
—
—
—
—
—
—
—
cases:2.05%
controls:0.29%
cases:1.85%
controls:0.50%
5
41
332
3071
—
—
—
—
7
9
335
3130
6
15
318
2966
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.5e-01
3.9e-01
5.9e-01
—
1.1e+00
1.0e+00
9.7e-01
cases:12.17%
controls:10.67%
cases:8.43%
controls:5.86%
cases:2.03%
controls:1.13%
—
—
cases:2.62%
controls:0.85%
cases:7.60%
controls:2.93%
cases:11.42%
controls:4.66%
41
332
296
2780
29
186
315
2986
7
36
337
3136
—
9
27
335
3143
26
92
316
3047
37
139
287
2842
Cathetrisation of artery
TPH07 [2001309747]
6.5e-01
—
—
—
—
—
2.0e+00
cases:4.75%
controls:2.54%
—
—
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.40%
16
79
321
3033
—
—
—
—
—
9
12
315
2969
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.37%
—
—
—
—
—
—
8
11
316
2970
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
-5.1e-02
3.5e-01
—
—
1.3e+00
1.0e+00
8.8e-01
cases:7.42%
controls:7.78%
cases:6.10%
controls:4.38%
—
—
—
—
cases:2.03%
controls:0.54%
cases:6.43%
controls:2.39%
cases:8.33%
controls:3.62%
25
242
312
2870
21
139
323
3033
—
—
7
17
337
3153
22
75
320
3064
27
108
297
2873
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
6.3e-01
7.6e-01
-1.0e+50
—
—
1.1e+00
8.0e-01
cases:4.45%
controls:2.41%
cases:3.78%
controls:1.80%
cases:0.00%
controls:0.25%
—
—
—
—
cases:4.39%
controls:1.53%
cases:8.64%
controls:4.06%
15
75
322
3037
13
57
331
3115
0
8
344
3164
—
—
15
48
327
3091
28
121
296
2860
Sedation and analgesia
WX002 [2001310758]
1.4e+00
—
—
—
—
—
1.9e+00
cases:1.48%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.34%
5
12
332
3100
—
—
—
—
—
7
10
317
2971
Neurosurgery
14 [38004459]
1.4e+00
—
—
—
—
—
1.9e+00
cases:1.78%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:2.16%
controls:0.34%
6
14
331
3098
—
—
—
—
—
7
10
317
2971
Pediatric Cardiology
OMOP4821938 [45756805]
5.4e-01
6.5e-01
—
—
—
9.9e-01
8.9e-01
cases:8.31%
controls:5.01%
cases:4.65%
controls:2.49%
—
—
—
—
—
—
cases:5.85%
controls:2.26%
cases:7.72%
controls:3.32%
28
156
309
2956
16
79
328
3093
—
—
—
20
71
322
3068
25
99
299
2882
Respiratory and circulatory monitoring
WX700 [2001310817]
7.1e-01
—
—
—
—
—
1.9e+00
cases:5.64%
controls:2.86%
—
—
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.44%
19
89
318
3023
—
—
—
—
—
9
13
315
2968
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
6.6e-01
7.2e-01
-1.0e+50
—
—
1.1e+00
7.8e-01
cases:4.15%
controls:2.19%
cases:3.49%
controls:1.73%
cases:0.00%
controls:0.22%
—
—
—
—
cases:4.09%
controls:1.47%
cases:8.02%
controls:3.86%
14
68
323
3044
12
55
332
3117
0
7
344
3165
—
—
14
46
328
3093
26
115
298
2866
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.2e-01
5.1e-01
5.8e-01
—
1.0e+00
1.0e+00
7.9e-01
cases:13.95%
controls:12.60%
cases:11.05%
controls:6.97%
cases:2.62%
controls:1.48%
—
—
cases:3.78%
controls:1.36%
cases:10.23%
controls:3.92%
cases:17.28%
controls:8.69%
47
392
290
2720
38
221
306
2951
9
47
335
3125
—
13
43
331
3127
35
123
307
3016
56
259
268
2722
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2.8e-01
5.8e-01
—
—
—
—
1.8e+00
cases:2.37%
controls:1.80%
cases:1.45%
controls:0.82%
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.57%
8
56
329
3056
5
26
339
3146
—
—
—
—
11
17
313
2964
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.2e-01
5.1e-01
6.2e-01
—
1.1e+00
1.1e+00
7.5e-01
cases:13.95%
controls:12.60%
cases:11.05%
controls:6.97%
cases:2.62%
controls:1.42%
—
—
cases:3.78%
controls:1.32%
cases:10.23%
controls:3.82%
cases:16.67%
controls:8.65%
47
392
290
2720
38
221
306
2951
9
45
335
3127
—
13
42
331
3128
35
120
307
3019
54
258
270
2723
Emergency Room Visit
ER [9203]
4.8e-01
2.9e-01
9.7e-01
—
7.9e-01
7.1e-01
5.7e-01
cases:41.25%
controls:30.24%
cases:13.37%
controls:10.37%
cases:2.62%
controls:1.01%
—
—
cases:1.45%
controls:0.66%
cases:14.04%
controls:7.42%
cases:28.40%
controls:18.35%
139
941
198
2171
46
329
298
2843
9
32
335
3140
—
5
21
339
3149
48
233
294
2906
92
547
232
2434
Other lack of expected normal physiological development
R62.8 [45534460]
1.8e+00
—
—
—
—
—
—
cases:2.37%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
8
13
329
3099
—
—
—
—
—
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
2.6e-01
—
—
—
—
1.7e+00
4.1e-01
cases:1.78%
controls:1.38%
—
—
—
—
—
—
—
—
cases:2.34%
controls:0.41%
cases:1.85%
controls:1.24%
6
43
331
3069
—
—
—
—
8
13
334
3126
6
37
318
2944
furosemide; oral, parenteral
C03CA01 [21601518]
1.7e+00
—
—
—
—
—
—
cases:3.56%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
12
20
325
3092
—
—
—
—
—
—
Other and unspecified convulsions
R56.8 [45602033]
1.7e+00
—
—
—
—
—
1.9e+00
cases:4.15%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.27%
14
24
323
3088
—
—
—
—
—
6
8
318
2973
Supplier / Service Provider
OMOP5117446 [33004]
-6.7e-01
-6.6e-01
—
—
—
1.4e+00
1.7e+00
cases:8.01%
controls:14.49%
cases:4.07%
controls:7.60%
—
—
—
—
—
—
cases:2.05%
controls:0.51%
cases:8.33%
controls:1.68%
27
451
310
2661
14
241
330
2931
—
—
—
7
16
335
3123
27
50
297
2931
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
9.0e-01
1.3e+00
—
—
—
1.7e+00
1.1e+00
cases:3.86%
controls:1.61%
cases:2.91%
controls:0.79%
—
—
—
—
—
—
cases:2.63%
controls:0.51%
cases:3.40%
controls:1.17%
13
50
324
3062
10
25
334
3147
—
—
—
9
16
333
3123
11
35
313
2946
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.01%
controls:0.81%
—
—
—
—
—
—
13
24
311
2957
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
5.7e-01
1.1e-01
—
—
—
9.9e-01
6.3e-01
cases:10.68%
controls:6.33%
cases:4.36%
controls:3.91%
—
—
—
—
—
—
cases:7.31%
controls:2.84%
cases:13.58%
controls:7.75%
36
197
301
2915
15
124
329
3048
—
—
—
25
89
317
3050
44
231
280
2750
Intermittent exotropia
H50.31 [2000502353]
1.6e+00
1.5e+00
—
—
—
—
1.8e+00
cases:2.67%
controls:0.55%
cases:1.45%
controls:0.32%
—
—
—
—
—
—
—
—
cases:1.54%
controls:0.27%
9
17
328
3095
5
10
339
3162
—
—
—
—
5
8
319
2973
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.57%
—
—
—
—
—
—
9
17
315
2964
dexchlorpheniramine, combinations
R06AB52 [21603467]
6.5e-01
-1.0e+50
—
—
—
—
1.6e+00
cases:6.53%
controls:3.53%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.57%
22
110
315
3002
0
17
344
3155
—
—
—
—
9
17
315
2964
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.57%
—
—
—
—
—
—
9
17
315
2964
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.57%
—
—
—
—
—
—
9
17
315
2964
miconazole
D01AC02 [21601921]
1.6e+00
—
—
—
—
—
—
cases:2.97%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
10
19
327
3093
—
—
—
—
—
—
Corticotropin [Mass/volume] in Plasma
2141-0 [3035637]
9.8e-01
—
—
—
—
—
1.6e+00
cases:2.37%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:3.09%
controls:0.64%
8
28
329
3084
—
—
—
—
—
10
19
314
2962
Home Visit
OMOP4822459 [581476]
4.8e-01
8.9e-01
—
—
—
—
1.6e+00
cases:6.23%
controls:3.95%
cases:1.74%
controls:0.73%
—
—
—
—
—
—
—
—
cases:5.86%
controls:1.24%
21
123
316
2989
6
23
338
3149
—
—
—
—
19
37
305
2944
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
2.7e-01
-3.0e-02
—
—
—
1.1e+00
1.6e+00
cases:5.64%
controls:4.37%
cases:1.74%
controls:1.80%
—
—
—
—
—
—
cases:2.05%
controls:0.70%
cases:5.25%
controls:1.14%
19
136
318
2976
6
57
338
3115
—
—
—
7
22
335
3117
17
34
307
2947
Limited function/disability NOS
A28 [2002000162]
1.6e+00
—
—
—
—
—
—
cases:3.86%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
13
26
324
3086
—
—
—
—
—
—
Specific learning problem
P24 [2002000819]
1.5e+00
—
—
—
—
—
1.5e+00
cases:2.08%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:2.78%
controls:0.60%
7
14
330
3098
—
—
—
—
—
9
18
315
2963
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
7.0e-01
—
—
—
—
—
1.5e+00
cases:2.67%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
cases:3.70%
controls:0.84%
9
42
328
3070
—
—
—
—
—
12
25
312
2956
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2.7e-01
7.4e-01
—
—
—
1.1e+00
1.5e+00
cases:3.26%
controls:2.51%
cases:2.62%
controls:1.26%
—
—
—
—
—
—
cases:2.34%
controls:0.80%
cases:3.70%
controls:0.87%
11
78
326
3034
9
40
335
3132
—
—
—
8
25
334
3114
12
26
312
2955
INR in Blood by Coagulation assay
34714-6 [3032080]
5.6e-01
7.8e-01
—
—
—
1.5e+00
1.4e+00
cases:5.04%
controls:2.96%
cases:2.91%
controls:1.36%
—
—
—
—
—
—
cases:2.34%
controls:0.54%
cases:4.01%
controls:0.97%
17
92
320
3020
10
43
334
3129
—
—
—
8
17
334
3122
13
29
311
2952
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
7.1e-01
7.3e-01
—
—
-1.0e+50
8.8e-01
1.4e+00
cases:3.86%
controls:1.93%
cases:1.74%
controls:0.85%
—
—
—
—
cases:0.00%
controls:0.16%
cases:2.05%
controls:0.86%
cases:4.01%
controls:0.97%
13
60
324
3052
6
27
338
3145
—
—
0
5
344
3165
7
27
335
3112
13
29
311
2952
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
4.6e-01
5.0e-01
—
—
—
9.2e-01
1.4e+00
cases:2.37%
controls:1.51%
cases:1.45%
controls:0.88%
—
—
—
—
—
—
cases:2.05%
controls:0.83%
cases:3.40%
controls:0.84%
8
47
329
3065
5
28
339
3144
—
—
—
7
26
335
3113
11
25
313
2956
ECG with 12 standard connections
XF400 [2001303368]
2.0e-01
2.4e-01
-1.0e+50
—
-1.0e+50
1.4e+00
8.6e-01
cases:5.34%
controls:4.43%
cases:2.03%
controls:1.61%
cases:0.00%
controls:0.35%
—
—
cases:0.00%
controls:0.22%
cases:3.22%
controls:0.80%
cases:4.01%
controls:1.74%
18
138
319
2974
7
51
337
3121
0
11
344
3161
—
0
7
344
3163
11
25
331
3114
13
52
311
2929
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
3.4e-01
1.8e-01
—
—
—
1.2e+00
1.4e+00
cases:6.53%
controls:4.72%
cases:2.33%
controls:1.95%
—
—
—
—
—
—
cases:2.34%
controls:0.70%
cases:5.56%
controls:1.41%
22
147
315
2965
8
62
336
3110
—
—
—
8
22
334
3117
18
42
306
2939
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
3.3e-01
-1.2e-01
—
—
—
1.1e+00
1.4e+00
cases:6.53%
controls:4.79%
cases:1.74%
controls:1.95%
—
—
—
—
—
—
cases:2.34%
controls:0.76%
cases:6.17%
controls:1.58%
22
149
315
2963
6
62
338
3110
—
—
—
8
24
334
3115
20
47
304
2934
Abnormal growth retardation
E34.35 [2000501486]
1.4e+00
1.3e+00
-1.0e+50
—
—
—
1.4e+00
cases:2.97%
controls:0.74%
cases:1.45%
controls:0.41%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:1.54%
controls:0.37%
10
23
327
3089
5
13
339
3159
0
6
344
3166
—
—
—
5
11
319
2970
CBC panel - Blood by Automated count
58410-2 [40761511]
2.8e-02
-1.3e-02
5.7e-01
—
1.4e+00
6.2e-01
5.2e-01
cases:14.84%
controls:14.49%
cases:6.98%
controls:7.06%
cases:2.33%
controls:1.32%
—
—
cases:4.07%
controls:1.04%
cases:7.02%
controls:3.89%
cases:14.20%
controls:8.99%
50
451
287
2661
24
224
320
2948
8
42
336
3130
—
14
33
330
3137
24
122
318
3017
46
268
278
2713
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.4e-01
3.2e-01
5.8e-01
—
8.1e-01
7.8e-01
6.1e-01
cases:13.35%
controls:11.79%
cases:9.30%
controls:6.90%
cases:2.62%
controls:1.48%
—
—
cases:3.49%
controls:1.58%
cases:9.65%
controls:4.65%
cases:16.67%
controls:9.83%
45
367
292
2745
32
219
312
2953
9
47
335
3125
—
12
50
332
3120
33
146
309
2993
54
293
270
2688
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
9.9e-01
—
—
—
—
—
1.4e+00
cases:2.97%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:3.40%
controls:0.87%
10
35
327
3077
—
—
—
—
—
11
26
313
2955
Spirometry
127783003 [4133840]
8.5e-01
9.3e-01
—
—
—
1.3e+00
1.3e+00
cases:2.67%
controls:1.16%
cases:1.74%
controls:0.69%
—
—
—
—
—
—
cases:2.05%
controls:0.54%
cases:3.40%
controls:0.91%
9
36
328
3076
6
22
338
3150
—
—
—
7
17
335
3122
11
27
313
2954
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
3.8e-01
7.0e-01
—
—
—
1.1e+00
1.3e+00
cases:2.97%
controls:2.06%
cases:2.33%
controls:1.17%
—
—
—
—
—
—
cases:1.75%
controls:0.57%
cases:3.40%
controls:0.91%
10
64
327
3048
8
37
336
3135
—
—
—
6
18
336
3121
11
27
313
2954
Other stressful life events affecting family and household
Z63.7 [45537662]
9.9e-01
9.1e-01
—
—
—
1.4e+00
1.3e+00
cases:3.56%
controls:1.35%
cases:2.62%
controls:1.07%
—
—
—
—
—
—
cases:2.34%
controls:0.57%
cases:4.63%
controls:1.27%
12
42
325
3070
9
34
335
3138
—
—
—
8
18
334
3121
15
38
309
2943
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
4.1e-01
3.7e-01
—
—
—
8.7e-01
1.3e+00
cases:4.75%
controls:3.21%
cases:2.91%
controls:2.02%
—
—
—
—
—
—
cases:2.92%
controls:1.24%
cases:5.56%
controls:1.54%
16
100
321
3012
10
64
334
3108
—
—
—
10
39
332
3100
18
46
306
2935
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
2.7e-01
6.8e-02
—
—
—
1.1e+00
1.3e+00
cases:5.64%
controls:4.37%
cases:2.33%
controls:2.18%
—
—
—
—
—
—
cases:2.63%
controls:0.89%
cases:4.32%
controls:1.24%
19
136
318
2976
8
69
336
3103
—
—
—
9
28
333
3111
14
37
310
2944
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
6.1e-01
7.1e-01
-1.0e+50
—
—
1.1e+00
1.2e+00
cases:4.45%
controls:2.47%
cases:2.91%
controls:1.45%
cases:0.00%
controls:0.16%
—
—
—
—
cases:3.51%
controls:1.18%
cases:8.95%
controls:2.82%
15
77
322
3035
10
46
334
3126
0
5
344
3167
—
—
12
37
330
3102
29
84
295
2897
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
—
1.3e+00
—
—
—
1.1e+00
1.2e+00
—
—
cases:1.74%
controls:0.47%
—
—
—
—
—
—
cases:1.75%
controls:0.61%
cases:5.86%
controls:1.81%
—
6
15
338
3157
—
—
—
6
19
336
3120
19
54
305
2927
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.2e+00
—
—
—
—
—
7.9e-01
cases:4.75%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:1.14%
16
46
321
3066
—
—
—
—
—
8
34
316
2947
opium derivatives and expectorants
R05FA02 [21603439]
5.9e-01
-1.0e+50
—
—
—
—
1.2e+00
cases:7.42%
controls:4.24%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.94%
controls:1.54%
25
132
312
2980
0
30
344
3142
—
—
—
—
16
46
308
2935
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
5.9e-01
-1.0e+50
—
—
—
—
1.2e+00
cases:7.42%
controls:4.24%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.94%
controls:1.54%
25
132
312
2980
0
30
344
3142
—
—
—
—
16
46
308
2935
antibiotics in combination with corticosteroids
D01AA20 [21601918]
6.4e-01
1.4e+00
—
—
—
8.9e-01
1.2e+00
cases:7.12%
controls:3.89%
cases:2.33%
controls:0.57%
—
—
—
—
—
—
cases:1.46%
controls:0.61%
cases:4.94%
controls:1.54%
24
121
313
2991
8
18
336
3154
—
—
—
5
19
337
3120
16
46
308
2935
Intravenous general anesthesia
WX404 [2001310807]
3.5e-01
-1.1e-01
—
—
—
1.1e+00
1.2e+00
cases:10.39%
controls:7.55%
cases:2.33%
controls:2.59%
—
—
—
—
—
—
cases:3.80%
controls:1.34%
cases:4.94%
controls:1.54%
35
235
302
2877
8
82
336
3090
—
—
—
13
42
329
3097
16
46
308
2935
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
5.3e-01
1.3e+00
—
—
—
—
1.2e+00
cases:6.53%
controls:3.95%
cases:2.33%
controls:0.66%
—
—
—
—
—
—
—
—
cases:5.56%
controls:1.74%
22
123
315
2989
8
21
336
3151
—
—
—
—
18
52
306
2929
antibiotics in combination with other drugs
S01AA20 [21603571]
4.0e-01
4.6e-01
—
—
—
—
1.2e+00
cases:8.01%
controls:5.53%
cases:1.74%
controls:1.10%
—
—
—
—
—
—
—
—
cases:6.79%
controls:2.18%
27
172
310
2940
6
35
338
3137
—
—
—
—
22
65
302
2916
Insulin-like growth factor-I [Moles/volume] in Serum or Plasma
29775-4 [3014326]
9.5e-01
5.1e-01
—
—
—
9.0e-01
1.2e+00
cases:3.26%
controls:1.29%
cases:2.03%
controls:1.23%
—
—
—
—
—
—
cases:2.63%
controls:1.08%
cases:4.94%
controls:1.58%
11
40
326
3072
7
39
337
3133
—
—
—
9
34
333
3105
16
47
308
2934
chlorphenamine, combinations
R06AB54 [21603468]
6.0e-01
-1.0e+50
—
—
—
—
1.2e+00
cases:7.42%
controls:4.21%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.94%
controls:1.61%
25
131
312
2981
0
30
344
3142
—
—
—
—
16
48
308
2933
phenylephrine, combinations
R01BA53 [21603214]
6.0e-01
-1.0e+50
—
—
—
—
1.2e+00
cases:7.42%
controls:4.21%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.94%
controls:1.61%
25
131
312
2981
0
30
344
3142
—
—
—
—
16
48
308
2933
combinations of corticosteroids
D07XB30 [21602188]
4.0e-01
1.1e+00
—
—
—
6.6e-01
5.3e-01
cases:12.17%
controls:8.52%
cases:4.94%
controls:1.64%
—
—
—
—
—
—
cases:3.22%
controls:1.69%
cases:9.88%
controls:6.07%
41
265
296
2847
17
52
327
3120
—
—
—
11
53
331
3086
32
181
292
2800
combinations of corticosteroids
D07AB30 [21602118]
4.0e-01
1.1e+00
—
—
—
6.6e-01
5.3e-01
cases:12.17%
controls:8.52%
cases:4.94%
controls:1.64%
—
—
—
—
—
—
cases:3.22%
controls:1.69%
cases:9.88%
controls:6.07%
41
265
296
2847
17
52
327
3120
—
—
—
11
53
331
3086
32
181
292
2800
Headache
R51.80 [2000503603]
1.1e+00
2.8e-01
—
—
—
7.6e-01
2.3e-01
cases:4.15%
controls:1.38%
cases:1.45%
controls:1.10%
—
—
—
—
—
—
cases:1.75%
controls:0.83%
cases:3.70%
controls:2.95%
14
43
323
3069
5
35
339
3137
—
—
—
6
26
336
3113
12
88
312
2893
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
1.8e-01
4.6e-01
—
—
—
8.4e-01
1.1e+00
cases:3.26%
controls:2.73%
cases:2.03%
controls:1.29%
—
—
—
—
—
—
cases:1.75%
controls:0.76%
cases:5.56%
controls:1.88%
11
85
326
3027
7
41
337
3131
—
—
—
6
24
336
3115
18
56
306
2925
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
3.9e-01
4.7e-01
—
—
—
7.2e-01
1.1e+00
cases:5.34%
controls:3.66%
cases:4.07%
controls:2.59%
—
—
—
—
—
—
cases:4.68%
controls:2.33%
cases:11.11%
controls:3.92%
18
114
319
2998
14
82
330
3090
—
—
—
16
73
326
3066
36
117
288
2864
Other specified counselling
Z71.8 [45581061]
3.8e-01
—
—
—
—
—
1.1e+00
cases:3.56%
controls:2.47%
—
—
—
—
—
—
—
—
—
—
cases:7.10%
controls:2.45%
12
77
325
3035
—
—
—
—
—
23
73
301
2908
Emergency Room and Inpatient Visit
ERIP [262]
2.3e-01
2.3e-01
—
—
—
1.3e+00
1.1e+00
cases:3.86%
controls:3.08%
cases:1.74%
controls:1.39%
—
—
—
—
—
—
cases:2.34%
controls:0.67%
cases:4.63%
controls:1.58%
13
96
324
3016
6
44
338
3128
—
—
—
8
21
334
3118
15
47
309
2934
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
3.3e-01
3.7e-01
—
—
—
—
1.1e+00
cases:2.97%
controls:2.15%
cases:1.45%
controls:1.01%
—
—
—
—
—
—
—
—
cases:4.32%
controls:1.48%
10
67
327
3045
5
32
339
3140
—
—
—
—
14
44
310
2937
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
-2.1e-01
2.5e-02
—
—
—
—
1.1e+00
cases:3.56%
controls:4.34%
cases:1.74%
controls:1.70%
—
—
—
—
—
—
—
—
cases:4.01%
controls:1.38%
12
135
325
2977
6
54
338
3118
—
—
—
—
13
41
311
2940
Gas panel - Venous blood
24339-4 [3000991]
1.4e-01
2.8e-01
—
—
—
7.1e-01
1.1e+00
cases:7.42%
controls:6.52%
cases:4.07%
controls:3.12%
—
—
—
—
—
—
cases:3.80%
controls:1.91%
cases:7.72%
controls:2.75%
25
203
312
2909
14
99
330
3073
—
—
—
13
60
329
3079
25
82
299
2899
12 lead EKG panel
34534-8 [3044889]
3.9e-01
—
—
—
—
1.2e+00
1.1e+00
cases:2.67%
controls:1.83%
—
—
—
—
—
—
—
—
cases:1.46%
controls:0.45%
cases:6.17%
controls:2.18%
9
57
328
3055
—
—
—
—
5
14
337
3125
20
65
304
2916
dextromethorphan, combinations; oral
N07XX59 [43534835]
6.1e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:7.42%
controls:4.18%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.32%
controls:1.51%
25
130
312
2982
0
30
344
3142
—
—
—
—
14
45
310
2936
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
6.1e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:7.42%
controls:4.18%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.32%
controls:1.51%
25
130
312
2982
0
30
344
3142
—
—
—
—
14
45
310
2936
promethazine, combinations
R06AD52 [21603489]
6.1e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:7.42%
controls:4.18%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.32%
controls:1.51%
25
130
312
2982
0
30
344
3142
—
—
—
—
14
45
310
2936
cough suppressants and expectorants
R05FB02 [21603442]
6.1e-01
-1.0e+50
—
—
—
—
1.1e+00
cases:7.42%
controls:4.18%
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.32%
controls:1.51%
25
130
312
2982
0
30
344
3142
—
—
—
—
14
45
310
2936
Plastic And Reconstructive Surgery
24 [38004467]
4.0e-01
9.3e-01
—
—
—
1.3e+00
1.1e+00
cases:2.37%
controls:1.61%
cases:1.74%
controls:0.69%
—
—
—
—
—
—
cases:2.05%
controls:0.57%
cases:4.32%
controls:1.54%
8
50
329
3062
6
22
338
3150
—
—
—
7
18
335
3121
14
46
310
2935
Infiltration anesthesia
WX110 [2001310767]
4.2e-01
3.0e-01
—
—
—
1.1e+00
7.3e-02
cases:9.50%
controls:6.43%
cases:4.36%
controls:3.28%
—
—
—
—
—
—
cases:7.31%
controls:2.68%
cases:12.35%
controls:11.57%
32
200
305
2912
15
104
329
3068
—
—
—
25
84
317
3055
40
345
284
2636
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
6.5e-02
5.6e-01
—
—
—
6.0e-01
1.1e+00
cases:2.67%
controls:2.51%
cases:3.20%
controls:1.86%
—
—
—
—
—
—
cases:2.92%
controls:1.62%
cases:5.56%
controls:2.01%
9
78
328
3034
11
59
333
3113
—
—
—
10
51
332
3088
18
60
306
2921
Short blood count panel - Blood
55429-5 [40758558]
1.0e-01
-9.3e-02
—
—
—
7.7e-01
1.0e+00
cases:9.20%
controls:8.39%
cases:3.49%
controls:3.81%
—
—
—
—
—
—
cases:3.51%
controls:1.66%
cases:7.10%
controls:2.62%
31
261
306
2851
12
121
332
3051
—
—
—
12
52
330
3087
23
78
301
2903
Other and unspecified abdominal pain
R10.4 [45568113]
-4.7e-02
3.3e-01
—
—
—
4.6e-01
1.0e+00
cases:3.56%
controls:3.73%
cases:1.74%
controls:1.26%
—
—
—
—
—
—
cases:1.75%
controls:1.12%
cases:8.64%
controls:3.25%
12
116
325
2996
6
40
338
3132
—
—
—
6
35
336
3104
28
97
296
2884
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-9.5e-03
7.4e-02
5.7e-01
—
1.0e+00
4.5e-01
2.3e-01
cases:18.40%
controls:18.54%
cases:14.24%
controls:13.37%
cases:5.23%
controls:3.03%
—
—
cases:6.10%
controls:2.27%
cases:14.33%
controls:9.62%
cases:21.91%
controls:18.18%
62
577
275
2535
49
424
295
2748
18
96
326
3076
—
21
72
323
3098
49
302
293
2837
71
542
253
2439
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
5.3e-01
1.7e-01
1.4e+00
—
—
9.4e-01
1.0e+00
cases:6.53%
controls:3.95%
cases:2.62%
controls:2.21%
cases:2.03%
controls:0.50%
—
—
—
—
cases:3.51%
controls:1.40%
cases:6.48%
controls:2.45%
22
123
315
2989
9
70
335
3102
7
16
337
3156
—
—
12
44
330
3095
21
73
303
2908
General anaesthesia
WX402 [2001310806]
2.4e-01
1.6e-01
—
—
-1.0e+50
6.4e-01
1.0e+00
cases:4.15%
controls:3.31%
cases:2.03%
controls:1.73%
—
—
—
—
cases:0.00%
controls:0.19%
cases:2.92%
controls:1.56%
cases:7.41%
controls:2.85%
14
103
323
3009
7
55
337
3117
—
—
0
6
344
3164
10
49
332
3090
24
85
300
2896
Urgent procedure
ZXD05 [2001311386]
1.0e+00
6.5e-01
—
—
—
1.1e+00
6.7e-01
cases:8.90%
controls:3.47%
cases:2.33%
controls:1.23%
—
—
—
—
—
—
cases:1.46%
controls:0.48%
cases:3.09%
controls:1.61%
30
108
307
3004
8
39
336
3133
—
—
—
5
15
337
3124
10
48
314
2933
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
4.3e-01
8.0e-01
—
—
—
9.4e-01
9.9e-01
cases:8.61%
controls:5.78%
cases:5.81%
controls:2.71%
—
—
—
—
—
—
cases:4.97%
controls:2.01%
cases:10.19%
controls:4.03%
29
180
308
2932
20
86
324
3086
—
—
—
17
63
325
3076
33
120
291
2861
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-5.3e-03
7.9e-02
5.8e-01
—
9.9e-01
4.6e-01
2.5e-01
cases:18.40%
controls:18.48%
cases:14.24%
controls:13.30%
cases:5.23%
controls:2.99%
—
—
cases:5.81%
controls:2.24%
cases:14.33%
controls:9.59%
cases:22.22%
controls:18.15%
62
575
275
2537
49
422
295
2750
18
95
326
3077
—
20
71
324
3099
49
301
293
2838
72
541
252
2440
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-5.3e-03
7.9e-02
5.8e-01
—
9.9e-01
4.6e-01
2.4e-01
cases:18.40%
controls:18.48%
cases:14.24%
controls:13.30%
cases:5.23%
controls:2.99%
—
—
cases:5.81%
controls:2.24%
cases:14.33%
controls:9.59%
cases:21.91%
controls:18.05%
62
575
275
2537
49
422
295
2750
18
95
326
3077
—
20
71
324
3099
49
301
293
2838
71
538
253
2443
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-5.3e-03
7.9e-02
5.8e-01
—
9.9e-01
4.6e-01
2.4e-01
cases:18.40%
controls:18.48%
cases:14.24%
controls:13.30%
cases:5.23%
controls:2.99%
—
—
cases:5.81%
controls:2.24%
cases:14.33%
controls:9.59%
cases:21.91%
controls:18.01%
62
575
275
2537
49
422
295
2750
18
95
326
3077
—
20
71
324
3099
49
301
293
2838
71
537
253
2444
Platelets [#/volume] in Blood
26515-7 [3007461]
-5.3e-03
7.9e-02
5.8e-01
—
9.9e-01
4.6e-01
2.4e-01
cases:18.40%
controls:18.48%
cases:14.24%
controls:13.30%
cases:5.23%
controls:2.99%
—
—
cases:5.81%
controls:2.24%
cases:14.33%
controls:9.59%
cases:21.91%
controls:18.05%
62
575
275
2537
49
422
295
2750
18
95
326
3077
—
20
71
324
3099
49
301
293
2838
71
538
253
2443
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-5.3e-03
7.9e-02
5.8e-01
—
9.9e-01
4.6e-01
2.4e-01
cases:18.40%
controls:18.48%
cases:14.24%
controls:13.30%
cases:5.23%
controls:2.99%
—
—
cases:5.81%
controls:2.24%
cases:14.33%
controls:9.59%
cases:21.91%
controls:18.05%
62
575
275
2537
49
422
295
2750
18
95
326
3077
—
20
71
324
3099
49
301
293
2838
71
538
253
2443
MCH [Entitic mass]
28539-5 [3035941]
-5.3e-03
7.9e-02
5.8e-01
—
9.9e-01
4.6e-01
2.4e-01
cases:18.40%
controls:18.48%
cases:14.24%
controls:13.30%
cases:5.23%
controls:2.99%
—
—
cases:5.81%
controls:2.24%
cases:14.33%
controls:9.59%
cases:21.91%
controls:18.05%
62
575
275
2537
49
422
295
2750
18
95
326
3077
—
20
71
324
3099
49
301
293
2838
71
538
253
2443
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
4.8e-02
5.3e-01
1.3e+00
—
—
8.4e-01
9.9e-01
cases:7.12%
controls:6.81%
cases:5.52%
controls:3.34%
cases:1.74%
controls:0.50%
—
—
—
—
cases:4.39%
controls:1.94%
cases:7.72%
controls:3.02%
24
212
313
2900
19
106
325
3066
6
16
338
3156
—
—
15
61
327
3078
25
90
299
2891
Examination of eyes and vision
Z01.0 [45566391]
4.7e-01
1.1e-01
—
—
—
9.7e-01
2.8e-01
cases:7.42%
controls:4.79%
cases:2.33%
controls:2.08%
—
—
—
—
—
—
cases:4.97%
controls:1.94%
cases:6.79%
controls:5.20%
25
149
312
2963
8
66
336
3106
—
—
—
17
61
325
3078
22
155
302
2826
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
4.8e-02
2.5e-01
—
—
—
6.7e-01
9.7e-01
cases:6.82%
controls:6.52%
cases:4.36%
controls:3.44%
—
—
—
—
—
—
cases:3.80%
controls:1.98%
cases:7.41%
controls:2.95%
23
203
314
2909
15
109
329
3063
—
—
—
13
62
329
3077
24
88
300
2893
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
1.3e-01
1.8e-01
—
—
—
6.6e-01
9.7e-01
cases:7.42%
controls:6.56%
cases:4.07%
controls:3.44%
—
—
—
—
—
—
cases:3.80%
controls:2.01%
cases:7.41%
controls:2.95%
25
204
312
2908
14
109
330
3063
—
—
—
13
63
329
3076
24
88
300
2893
Laceration/cut
S18 [2002000983]
1.2e-02
—
—
—
—
—
9.6e-01
cases:2.37%
controls:2.35%
—
—
—
—
—
—
—
—
—
—
cases:6.79%
controls:2.72%
8
73
329
3039
—
—
—
—
—
22
81
302
2900
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
-9.9e-02
6.1e-02
—
—
—
1.3e-01
9.4e-01
cases:7.72%
controls:8.45%
cases:3.78%
controls:3.56%
—
—
—
—
—
—
cases:2.63%
controls:2.33%
cases:8.95%
controls:3.69%
26
263
311
2849
13
113
331
3059
—
—
—
9
73
333
3066
29
110
295
2871
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-3.8e-04
1.3e-01
6.0e-01
—
9.4e-01
5.5e-01
4.5e-01
cases:17.51%
controls:17.51%
cases:13.95%
controls:12.42%
cases:4.94%
controls:2.77%
—
—
cases:5.23%
controls:2.11%
cases:13.74%
controls:8.44%
cases:20.06%
controls:13.82%
59
545
278
2567
48
394
296
2778
17
88
327
3084
—
18
67
326
3103
47
265
295
2874
65
412
259
2569
Leukocytes [#/volume] in Urine
30405-5 [3018095]
-2.0e-01
-1.1e-01
—
—
—
9.6e-02
9.3e-01
cases:5.64%
controls:6.81%
cases:3.49%
controls:3.88%
—
—
—
—
—
—
cases:3.22%
controls:2.93%
cases:9.57%
controls:3.99%
19
212
318
2900
12
123
332
3049
—
—
—
11
92
331
3047
31
119
293
2862
pH of Venous blood
2746-6 [3012544]
9.2e-02
1.2e-01
—
—
—
5.8e-01
9.2e-01
cases:7.42%
controls:6.81%
cases:4.07%
controls:3.63%
—
—
—
—
—
—
cases:3.80%
controls:2.17%
cases:7.41%
controls:3.09%
25
212
312
2900
14
115
330
3057
—
—
—
13
68
329
3071
24
92
300
2889
Base excess in Venous blood by calculation
1927-3 [3002032]
9.2e-02
1.3e-01
—
—
—
5.9e-01
9.2e-01
cases:7.42%
controls:6.81%
cases:4.07%
controls:3.59%
—
—
—
—
—
—
cases:3.80%
controls:2.13%
cases:7.41%
controls:3.09%
25
212
312
2900
14
114
330
3058
—
—
—
13
67
329
3072
24
92
300
2889
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
9.2e-02
1.2e-01
—
—
—
5.8e-01
9.2e-01
cases:7.42%
controls:6.81%
cases:4.07%
controls:3.63%
—
—
—
—
—
—
cases:3.80%
controls:2.17%
cases:7.41%
controls:3.09%
25
212
312
2900
14
115
330
3057
—
—
—
13
68
329
3071
24
92
300
2889
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
1.6e-01
1.2e-02
—
—
—
-2.6e-01
9.1e-01
cases:4.75%
controls:4.08%
cases:2.62%
controls:2.59%
—
—
—
—
—
—
cases:1.75%
controls:2.26%
cases:9.88%
controls:4.23%
16
127
321
2985
9
82
335
3090
—
—
—
6
71
336
3068
32
126
292
2855
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
1.7e-01
2.5e-02
—
—
—
-2.6e-01
8.7e-01
cases:4.75%
controls:4.02%
cases:2.62%
controls:2.55%
—
—
—
—
—
—
cases:1.75%
controls:2.26%
cases:9.57%
controls:4.23%
16
125
321
2987
9
81
335
3091
—
—
—
6
71
336
3068
31
126
293
2855
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
1.8e-01
2.5e-02
—
—
—
-2.6e-01
8.7e-01
cases:4.75%
controls:3.98%
cases:2.62%
controls:2.55%
—
—
—
—
—
—
cases:1.75%
controls:2.26%
cases:9.57%
controls:4.23%
16
124
321
2988
9
81
335
3091
—
—
—
6
71
336
3068
31
126
293
2855
Chronic mucoid otitis media
H65.3 [45567124]
8.6e-01
6.5e-01
-1.0e+50
—
—
6.5e-01
9.4e-01
cases:6.23%
controls:2.73%
cases:2.33%
controls:1.23%
cases:0.00%
controls:0.32%
—
—
—
—
cases:1.75%
controls:0.92%
cases:2.78%
controls:1.11%
21
85
316
3027
8
39
336
3133
0
10
344
3162
—
—
6
29
336
3110
9
33
315
2948
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
-9.5e-02
2.1e-01
—
—
—
2.0e-02
8.6e-01
cases:7.72%
controls:8.42%
cases:4.94%
controls:4.04%
—
—
—
—
—
—
cases:3.22%
controls:3.15%
cases:11.11%
controls:5.03%
26
262
311
2850
17
128
327
3044
—
—
—
11
99
331
3040
36
150
288
2831
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
5.9e-01
7.0e-01
-1.0e+50
—
—
8.9e-01
8.6e-01
cases:8.01%
controls:4.63%
cases:3.20%
controls:1.61%
cases:0.00%
controls:0.38%
—
—
—
—
cases:3.51%
controls:1.47%
cases:8.64%
controls:3.86%
27
144
310
2968
11
51
333
3121
0
12
344
3160
—
—
12
46
330
3093
28
115
296
2866
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
8.5e-01
—
—
—
—
4.3e-01
3.6e-01
cases:7.12%
controls:3.18%
—
—
—
—
—
—
—
—
cases:1.46%
controls:0.96%
cases:3.40%
controls:2.38%
24
99
313
3013
—
—
—
—
5
30
337
3109
11
71
313
2910
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
-2.3e-01
-1.2e-01
—
—
—
2.1e-01
8.4e-01
cases:5.34%
controls:6.65%
cases:3.20%
controls:3.59%
—
—
—
—
—
—
cases:3.22%
controls:2.61%
cases:8.02%
controls:3.62%
18
207
319
2905
11
114
333
3058
—
—
—
11
82
331
3057
26
108
298
2873
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
-2.7e-01
-4.0e-02
—
—
—
1.2e-01
8.3e-01
cases:5.34%
controls:6.91%
cases:3.49%
controls:3.63%
—
—
—
—
—
—
cases:2.92%
controls:2.61%
cases:8.02%
controls:3.66%
18
215
319
2897
12
115
332
3057
—
—
—
10
82
332
3057
26
109
298
2872
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
6.6e-01
7.4e-01
-1.0e+50
—
—
1.0e+00
7.9e-01
cases:4.15%
controls:2.19%
cases:3.49%
controls:1.70%
cases:0.00%
controls:0.22%
—
—
—
—
cases:4.09%
controls:1.50%
cases:8.02%
controls:3.79%
14
68
323
3044
12
54
332
3118
0
7
344
3165
—
—
14
47
328
3092
26
113
298
2868
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
-4.1e-02
-4.0e-01
—
—
—
7.1e-01
7.9e-01
cases:6.53%
controls:6.78%
cases:1.74%
controls:2.59%
—
—
—
—
—
—
cases:2.63%
controls:1.31%
cases:7.41%
controls:3.49%
22
211
315
2901
6
82
338
3090
—
—
—
9
41
333
3098
24
104
300
2877
Laboratory Visit
OMOP4822461 [32036]
-2.0e-02
1.1e-01
3.1e-01
1.9e+00
7.9e-01
1.1e-01
1.1e-01
cases:21.66%
controls:22.01%
cases:21.22%
controls:19.45%
cases:7.27%
controls:5.42%
cases:1.74%
controls:0.25%
cases:8.72%
controls:4.16%
cases:18.71%
controls:17.08%
cases:28.40%
controls:26.13%
73
685
264
2427
73
617
271
2555
25
172
319
3000
6
8
338
3164
30
132
314
3038
64
536
278
2603
92
779
232
2202
Paediatric Clinical Immunology and Allergy
255 [44777768]
8.4e-02
4.6e-01
-1.0e+50
—
—
5.0e-01
7.9e-01
cases:5.64%
controls:5.21%
cases:4.94%
controls:3.18%
cases:0.00%
controls:0.57%
—
—
—
—
cases:4.68%
controls:2.90%
cases:8.02%
controls:3.82%
19
162
318
2950
17
101
327
3071
0
18
344
3154
—
—
16
91
326
3048
26
114
298
2867
Normoblasts [#/volume] in Blood
715-3 [3021589]
1.1e-01
-7.3e-04
4.4e-01
—
3.1e-01
6.3e-01
6.6e-01
cases:10.68%
controls:9.70%
cases:6.40%
controls:6.40%
cases:2.33%
controls:1.51%
—
—
cases:1.45%
controls:1.07%
cases:7.02%
controls:3.85%
cases:12.04%
controls:6.61%
36
302
301
2810
22
203
322
2969
8
48
336
3124
—
5
34
339
3136
24
121
318
3018
39
197
285
2784
General anesthesia, balanced
WX408 [2001310808]
6.6e-01
1.5e-01
—
—
—
9.0e-01
9.1e-01
cases:12.46%
controls:6.88%
cases:2.91%
controls:2.52%
—
—
—
—
—
—
cases:2.63%
controls:1.08%
cases:4.94%
controls:2.05%
42
214
295
2898
10
80
334
3092
—
—
—
9
34
333
3105
16
61
308
2920
Telehealth
OMOP5556618 [722455]
1.6e-01
2.9e-01
8.0e-01
—
1.4e+00
7.5e-01
5.7e-01
cases:17.21%
controls:15.04%
cases:6.69%
controls:5.08%
cases:1.74%
controls:0.79%
—
—
cases:2.03%
controls:0.50%
cases:7.02%
controls:3.44%
cases:14.81%
controls:8.96%
58
468
279
2644
23
161
321
3011
6
25
338
3147
—
7
16
337
3154
24
108
318
3031
48
267
276
2714
salbutamol; inhalant
R03AC02 [21603256]
4.2e-01
5.5e-01
—
—
1.0e+00
5.8e-01
5.6e-01
cases:18.40%
controls:12.95%
cases:12.50%
controls:7.63%
—
—
—
—
cases:3.20%
controls:1.17%
cases:11.11%
controls:6.56%
cases:20.06%
controls:12.58%
62
403
275
2709
43
242
301
2930
—
—
11
37
333
3133
38
206
304
2933
65
375
259
2606
cetirizine; oral
R06AE07 [21603497]
5.5e-01
2.6e-01
—
—
-1.0e+50
5.8e-01
4.8e-01
cases:15.73%
controls:9.74%
cases:6.40%
controls:5.01%
—
—
—
—
cases:0.00%
controls:0.57%
cases:6.43%
controls:3.70%
cases:12.96%
controls:8.45%
53
303
284
2809
22
159
322
3013
—
—
0
18
344
3152
22
116
320
3023
42
252
282
2729
naproxen; oral, rectal
M01AE02 [21603968]
5.3e-01
3.1e-01
—
—
—
1.9e-01
4.2e-02
cases:25.52%
controls:16.74%
cases:6.10%
controls:4.57%
—
—
—
—
—
—
cases:4.39%
controls:3.66%
cases:8.64%
controls:8.32%
86
521
251
2591
21
145
323
3027
—
—
—
15
115
327
3024
28
248
296
2733
naproxcinod
M01AE18 [40254094]
5.3e-01
3.1e-01
—
—
—
1.9e-01
4.2e-02
cases:25.52%
controls:16.74%
cases:6.10%
controls:4.57%
—
—
—
—
—
—
cases:4.39%
controls:3.66%
cases:8.64%
controls:8.32%
86
521
251
2591
21
145
323
3027
—
—
—
15
115
327
3024
28
248
296
2733
azithromycin; oral, parenteral
J01FA10 [21602978]
4.6e-01
5.1e-01
1.2e+00
—
—
6.6e-01
4.2e-01
cases:33.23%
controls:23.84%
cases:8.72%
controls:5.42%
cases:1.74%
controls:0.54%
—
—
—
—
cases:8.19%
controls:4.40%
cases:15.74%
controls:10.90%
112
742
225
2370
30
172
314
3000
6
17
338
3155
—
—
28
138
314
3001
51
325
273
2656
formoterol and budesonide
R03AK07 [21603281]
—
—
—
—
—
—
7.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:1.24%
—
—
—
—
—
—
8
37
316
2944
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
337
3102
—
—
—
—
—
—
Teaching
WZC30 [2001310891]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
0
6
344
3164
—
—
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:0.27%
—
—
—
—
—
—
6
8
318
2973
Transfer of stem cells from registered domestic donator
WW304 [2001310593]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
0
5
344
3167
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
—
—
—
—
—
—
9.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.54%
controls:0.60%
—
—
—
—
—
—
5
18
319
2963
Angioneurotic oedema
T78.3 [45551447]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
337
3107
—
—
—
—
—
—
Arm symptom/complaint
L09 [2002000633]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
0
8
337
3104
—
—
—
—
—
0
10
324
2971
Operation on frenulum of tongue
EJC20 [2001302185]
1.6e+00
—
—
—
—
—
—
cases:1.78%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
6
11
331
3101
—
—
—
—
—
—
Pap smear
SPAT1193 [2001700294]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
324
2975
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
-1.0e+50
—
—
—
-1.0e+50
1.0e+00
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:0.00%
controls:0.25%
cases:1.85%
controls:0.67%
—
0
6
344
3166
—
—
—
0
8
342
3131
6
20
318
2961
CT examination of mouth and soft tissues of neck
EN1AD [2001302280]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
324
2976
Other oral or dental procedure
SXC05 [2001310586]
—
—
—
—
—
—
-2.4e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.63%
controls:5.84%
—
—
—
—
—
—
15
174
309
2807
Renal hypoplasia, unilateral
Q60.3 [45577737]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.22%
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.17%
0
7
337
3105
0
6
344
3166
—
—
—
0
5
342
3134
0
5
324
2976
glycerol; rectal
A06AG04 [21600587]
-2.6e-01
—
—
—
—
—
—
cases:2.67%
controls:3.44%
—
—
—
—
—
—
—
—
—
—
—
—
9
107
328
3005
—
—
—
—
—
—
etanercept; parenteral
L04AB01 [21603908]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
0
5
337
3107
0
5
344
3167
—
—
—
—
—
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
6.0e-01
4.4e-01
—
—
—
4.8e-01
5.0e-01
cases:3.86%
controls:2.15%
cases:2.03%
controls:1.32%
—
—
—
—
—
—
cases:2.05%
controls:1.27%
cases:3.40%
controls:2.08%
13
67
324
3045
7
42
337
3130
—
—
—
7
40
335
3099
11
62
313
2919
Exposure to unspecified factor
X59 [45756412]
—
—
—
—
—
—
1.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.85%
controls:1.68%
—
—
—
—
—
—
6
50
318
2931
Two-surface restoration
SFA20 [2001310359]
2.6e-01
5.7e-01
—
—
-1.0e+50
3.2e-01
-1.6e-01
cases:2.97%
controls:2.31%
cases:2.33%
controls:1.32%
—
—
—
—
cases:0.00%
controls:0.22%
cases:2.92%
controls:2.13%
cases:6.17%
controls:7.18%
10
72
327
3040
8
42
336
3130
—
—
0
7
344
3163
10
67
332
3072
20
214
304
2767
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
—
7.5e-01
—
—
—
1.3e+00
1.2e+00
—
—
cases:1.45%
controls:0.69%
—
—
—
—
—
—
cases:1.46%
controls:0.41%
cases:2.16%
controls:0.67%
—
5
22
339
3150
—
—
—
5
13
337
3126
7
20
317
2961
Pruritus
S02 [2002000967]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
337
3107
—
—
—
—
—
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
337
3106
—
—
—
—
—
—
Open wound on lip
S01.51 [2000503614]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
0
10
324
2971
Acute suppurative otitis media
H66.0 [45572040]
-1.8e-02
3.4e-01
—
—
1.9e+00
1.1e-01
2.6e-01
cases:11.57%
controls:11.76%
cases:4.07%
controls:2.93%
—
—
—
—
cases:1.45%
controls:0.22%
cases:2.63%
controls:2.36%
cases:4.94%
controls:3.86%
39
366
298
2746
14
93
330
3079
—
—
5
7
339
3163
9
74
333
3065
16
115
308
2866
Nephrology
39 [38004479]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
337
3107
—
—
—
—
—
—
Congenital stenosis of aortic valve
Q23.0 [45587449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
324
2976
Upper respiratory infection acute
R74 [2002000942]
-5.0e-01
—
-1.0e+50
—
—
7.0e-02
4.1e-01
cases:4.15%
controls:6.65%
—
—
cases:0.00%
controls:0.28%
—
—
—
—
cases:2.05%
controls:1.91%
cases:6.48%
controls:4.39%
14
207
323
2905
—
0
9
344
3163
—
—
7
60
335
3079
21
131
303
2850
Nail symptom/complaint
S22 [2002000987]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
8
324
2973
Influenza due to identified zoonotic or pandemic influenza virus
J09 [45755449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
324
2975
Juvenile idiopathic scoliosis
M41.1 [45601442]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
337
3107
—
—
—
—
—
—
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
0
7
344
3165
—
—
—
—
—
desloratadine; oral
R06AX27 [21603526]
4.2e-01
2.7e-01
—
—
-1.0e+50
8.4e-02
3.0e-01
cases:9.50%
controls:6.43%
cases:4.36%
controls:3.37%
—
—
—
—
cases:0.00%
controls:0.41%
cases:3.80%
controls:3.50%
cases:8.64%
controls:6.57%
32
200
305
2912
15
107
329
3065
—
—
0
13
344
3157
13
110
329
3029
28
196
296
2785
ranitidine; oral, parenteral
A02BA02 [21600083]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
0
5
342
3134
—
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
6.6e-01
—
—
—
—
—
1.4e+00
cases:5.64%
controls:2.99%
—
—
—
—
—
—
—
—
—
—
cases:1.54%
controls:0.37%
19
93
318
3019
—
—
—
—
—
5
11
319
2970
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
10
344
3162
—
—
—
—
—
Microscopic observation [Identifier] in Isolate by Gram stain
87975-9 [36305247]
1.1e+00
—
—
—
—
—
—
cases:2.08%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
—
7
21
330
3091
—
—
—
—
—
—
BK virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
32284-2 [3000504]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
0
7
344
3163
—
—
hydrocortisone
C05AA01 [21601608]
3.4e-01
1.7e-01
—
—
—
-1.6e-01
3.9e-01
cases:16.32%
controls:12.18%
cases:3.78%
controls:3.22%
—
—
—
—
—
—
cases:2.34%
controls:2.74%
cases:9.26%
controls:6.44%
55
379
282
2733
13
102
331
3070
—
—
—
8
86
334
3053
30
192
294
2789
Comprehensive hearing test
SPAT1041 [2001700142]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
0
7
324
2974
pH of Urine
2756-5 [3015736]
1.7e-02
-2.4e-01
—
—
-1.0e+50
-7.0e-02
7.4e-01
cases:3.56%
controls:3.50%
cases:1.74%
controls:2.21%
—
—
—
—
cases:0.00%
controls:0.50%
cases:1.75%
controls:1.88%
cases:7.10%
controls:3.52%
12
109
325
3003
6
70
338
3102
—
—
0
16
344
3154
6
59
336
3080
23
105
301
2876
Adverse effects in the therapeutic use of bacterial vaccines
Y58 [45756619]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
337
3107
—
—
—
—
—
—
Parathyrin.intact [Moles/volume] in Serum or Plasma
14866-8 [3010566]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.22%
cases:0.00%
controls:0.28%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
0
7
337
3105
0
9
344
3163
—
—
—
0
10
342
3129
—
Foot and toes X-ray examination
NH3AA [2001308267]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
0
9
324
2972
Sodium [Moles/volume] in Urine
2955-3 [3003181]
1.3e+00
-1.0e+50
—
—
—
—
—
cases:1.48%
controls:0.42%
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
5
13
332
3099
0
5
344
3167
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
337
3105
—
—
—
—
—
—
Epstein Barr virus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
43730-1 [3043849]
—
—
—
—
—
9.3e-01
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:1.75%
controls:0.70%
cases:2.16%
controls:0.74%
—
—
—
—
—
6
22
336
3117
7
22
317
2959
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
1.4e+00
—
—
—
—
—
—
cases:2.37%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
8
18
329
3094
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
343
1510
3.52
51.98
22.6
12.4
1.22
1.23
mmol/l
1.75
335
1447
353
1605
3.46
50.30
18.3
11.1
1.22
1.23
mmol/l
1.84
335
1496
62
80
7.96
42.26
2.8
1.7
—
—
—
0
0
410
2185
3.23
42.06
8.5
6.1
121.53
108.75
u/l
2.26
392
2078
199
723
3.32
39.13
3.3
3.0
2.38
2.40
mmol/l
1.39
189
663
308
1493
2.85
35.63
5.3
3.2
67.39
68.23
nmol/l
0.22
298
1436
255
1119
2.93
35.54
10.3
8.8
38.35
38.33
g/l
0.02
242
1072
173
617
3.26
34.57
5.1
4.3
7.39
7.39
ph
0.01
123
392
280
1314
2.82
34.08
10.0
7.5
22.56
21.73
umol/l
0.10
265
1205
153
525
3.30
32.37
3.7
2.2
273.34
510.09
u/l
0.86
153
506
31
0
+∞
31.79
22.2
0.0
1339.77
—
nmol/l
—
31
0
29
0
+∞
29.72
17.3
0.0
18757.45
—
nmol/l
—
29
0
282
1436
2.54
27.71
9.5
7.2
—
—
—
0
0
107
326
3.51
27.02
18.5
16.1
106.34
105.24
mmol/l
1.16
107
326
173
700
2.82
26.91
16.5
10.1
1.31
1.36
mmol/l
1.01
165
667
355
2047
2.46
26.13
14.7
6.9
5.98
6.21
mmol/l
0.99
339
1861
204
930
2.57
24.78
4.5
5.0
8.06
9.21
mmol/l
1.75
186
890
170
710
2.71
24.63
21.4
10.5
—
—
—
0
0
121
421
3.10
24.50
1.6
1.3
19.77
19.20
nmol/l
0.16
110
390
178
766
2.65
24.26
2.0
1.4
99.83
97.77
pmol/l
0.20
86
413
179
774
2.64
24.15
11.3
10.1
0.73
1.05
mmol/l
0.63
148
638
293
1594
2.37
23.95
3.2
1.9
—
—
—
0
0
454
2997
2.56
23.81
5.2
3.3
14.67
14.58
pmol/l
0.35
430
2684
532
3820
3.13
23.22
25.7
9.8
139.61
139.40
mmol/l
1.63
527
3694
127
468
2.94
23.17
18.3
10.9
0.80
0.82
mmol/l
1.25
122
456
177
775
2.60
23.15
11.6
10.3
7.37
7.37
ph
0.00
133
532
532
3824
3.12
23.09
25.5
9.8
3.95
3.93
mmol/l
1.06
525
3676
49
94
5.22
22.58
2.5
3.4
4.40
5.74
index
0.23
30
64
38
59
6.36
21.76
3.9
5.3
1.54
1.74
umol/l
0.42
38
59
46
88
5.21
21.25
1.8
1.5
0.21
0.28
mg/l
0.46
19
40
119
443
2.88
21.19
7.8
7.1
6.20
6.73
umol/l
0.18
104
371
414
2697
2.32
21.07
16.3
10.0
3.64
3.56
e9/l
0.31
367
2216
391
2490
2.27
20.98
12.0
8.8
0.04
0.04
e9/l
0.13
344
2060
391
2495
2.27
20.80
11.9
8.8
0.59
0.56
e9/l
1.62
344
2062
399
2579
2.26
20.39
13.3
9.3
0.21
0.21
e9/l
0.32
362
2178
314
1845
2.20
20.35
11.0
9.8
—
—
—
0
0
75
218
3.53
20.14
29.7
13.9
-0.62
-0.09
mmol/l
0.47
64
185
496
3537
2.56
19.88
5.8
3.6
2.01
1.90
mu/l
1.56
476
3317
74
218
3.48
19.45
30.1
13.9
7.38
7.39
ph
0.07
26
75
402
2640
2.21
19.25
4.4
2.0
5.71
5.34
mmol/l
4.03
384
2428
125
501
2.68
19.21
4.1
2.9
12.49
14.09
umol/l
1.67
118
483
119
467
2.72
19.05
4.1
3.0
2.62
2.53
g/l
0.99
109
448
159
729
2.40
18.35
4.7
3.7
4.43
1.91
e6/l
1.76
89
373
393
2597
2.14
17.95
12.1
8.6
2.32
2.30
e9/l
0.12
356
2224
368
2374
2.11
17.88
12.3
9.0
0.61
0.64
%
0.53
355
2269
368
2388
2.09
17.42
12.3
9.0
8.49
8.44
%
0.15
355
2279
367
2380
2.09
17.39
12.2
8.9
2.99
3.21
%
0.96
354
2270
374
2475
2.05
16.35
11.7
8.6
50.96
50.10
%
0.64
364
2393
109
450
2.54
15.58
2.7
2.0
—
—
—
0
0
156
758
2.24
15.44
18.4
8.1
7.40
7.41
ph
2.03
135
595
146
691
2.28
15.39
16.6
7.7
—
—
—
0
0
376
2525
2.00
15.36
12.1
8.7
33.79
34.80
%
0.94
365
2440
87
325
2.75
15.15
2.9
2.1
4.42
6.17
u/l
2.16
62
210
62
194
3.22
14.75
3.4
3.7
5.11
5.27
pmol/l
0.52
62
184
21
9
22.57
14.68
1.0
1.4
—
—
—
0
0
71
247
2.91
14.08
2.2
2.4
2.41
2.41
mmol/l
0.16
58
212
53
156
3.39
13.89
38.9
17.6
93.75
96.44
%
0.80
53
156
91
363
2.58
13.89
15.1
5.6
1151.27
773.95
ng/l
0.42
71
296
547
4307
2.60
13.84
14.3
7.8
31.91
26.92
u/l
2.39
538
4188
149
740
2.17
13.81
4.9
3.5
0.50
0.66
e6/l
0.59
79
378
222
1281
1.97
13.68
6.0
3.9
10.32
47.54
e6/l
2.79
170
941
52
156
3.32
13.23
39.4
17.6
0.60
0.68
%
0.97
52
156
22
15
14.20
13.13
4.1
4.2
1.18
1.14
umol/l
0.14
22
15
254
1554
1.90
12.99
7.5
4.7
34.92
44.45
e6/l
0.29
176
998
110
497
2.31
12.75
2.3
1.6
—
—
—
0
0
69
250
2.79
12.68
2.0
1.8
0.00
0.00
estimate
—
7
72
46
131
3.47
12.68
1.9
1.8
21.99
30.85
ng/l
0.44
46
131
24
22
10.59
12.55
3.6
2.5
—
—
—
0
0
19
10
18.32
12.51
4.7
1.6
25.52
34.20
umol/l
—
19
10
103
462
2.31
12.12
5.6
2.9
778.92
1429.49
ng/l
0.85
68
257
197
1131
1.93
12.04
4.0
2.9
—
—
—
0
0
167
908
1.99
11.95
10.2
4.6
1.15
1.15
inr
0.04
131
740
171
940
1.97
11.85
3.5
2.6
1.02
2.83
kg/l
0.50
114
567
56
189
2.95
11.70
10.0
18.1
130.80
127.17
g/l
0.53
56
184
21
17
11.94
11.70
2.7
1.1
—
—
—
0
0
375
2647
1.83
11.69
5.2
3.0
36.13
35.84
mmol/mol
0.19
366
2543
18
10
17.33
11.67
4.9
1.4
42.40
40.90
umol/l
—
18
10
134
678
2.09
11.66
4.3
4.1
—
—
—
0
0
345
2380
1.81
11.55
12.8
10.3
0.00
0.00
e9/l
0.41
274
1811
198
1164
1.87
11.11
6.1
3.7
0.14
0.25
e6/l
0.81
142
832
72
287
2.53
10.94
2.2
2.6
24.53
36.34
u/l
3.30
60
241
136
707
2.03
10.94
18.3
8.0
9.69
9.80
kpa
0.25
131
688
141
743
2.01
10.92
4.5
2.7
593.83
592.04
mosm/kgh2o
0.03
130
662
129
659
2.05
10.88
7.3
3.6
1.19
1.58
mg/l
0.50
99
467
42
127
3.25
10.55
1.5
1.5
990.59
1026.90
nmol/l
0.09
32
92
75
311
2.43
10.48
3.1
2.1
5.98
6.38
iu/l
0.19
53
204
80
345
2.35
10.24
2.8
1.5
—
—
—
0
0
254
1643
1.76
10.21
4.2
2.9
6.44
6.32
ph
1.09
126
823
187
1109
1.83
10.04
2.1
1.9
1.49
1.21
mmol/l
3.97
175
1031
48
164
2.89
9.82
10.4
17.9
0.63
0.61
%
0.10
48
164
382
2798
1.73
9.60
3.9
2.4
1.27
1.09
mmol/l
4.65
368
2680
118
610
2.00
9.55
11.1
5.5
30.80
30.46
s
0.22
118
603
192
1167
1.78
9.41
6.2
3.6
—
3.33
estimate
—
0
6
143
803
1.87
9.02
4.6
2.9
8.28
5.89
e6/l
0.98
130
726
88
417
2.14
8.96
2.8
1.9
10.02
12.29
nmol/l
1.16
83
389
164
970
1.79
8.71
4.0
3.5
2.56
2.38
mg/l
0.62
149
877
410
3104
1.70
8.69
4.5
2.7
4.28
4.43
mmol/l
2.84
396
2989
145
827
1.84
8.68
3.3
2.1
—
—
—
0
0
35
107
3.19
8.66
4.6
3.3
7.31
7.35
ph
0.21
28
74
34
105
3.15
8.28
3.6
3.0
1701.77
1464.26
e6/l
0.38
26
62
536
4416
2.00
8.21
27.6
12.6
13.37
13.03
%
8.86
530
4351
404
3071
1.67
8.17
4.5
2.7
2.65
2.69
mmol/l
0.39
392
2938
37
123
2.93
7.96
2.4
4.8
33.50
271.44
e6/l
0.72
28
87
37
124
2.91
7.85
2.3
4.8
8.88
9.21
e6/l
0.01
25
84
400
3061
1.63
7.60
4.3
2.6
1.26
1.40
mmol/l
12.96
388
2925
97
507
1.94
7.52
7.3
6.1
1.58
1.38
%
1.21
91
483
237
1603
1.62
7.48
4.6
3.1
—
—
estimate
—
0
0
32
102
3.05
7.41
3.4
2.9
657.79
523.02
e6/l
0.50
24
56
36
124
2.83
7.29
2.1
4.6
3.22
3.40
mmol/l
1.11
36
119
109
600
1.85
7.21
3.0
2.0
59.42
48.35
ng/l
0.13
58
207
32
104
2.99
7.17
3.6
2.9
278.17
230.98
e6/l
0.27
24
60
24
66
3.50
7.01
6.9
5.2
—
—
—
0
0
34
116
2.85
7.01
3.2
1.9
—
—
—
0
0
34
116
2.85
7.01
3.2
1.9
—
—
—
0
0
34
116
2.85
7.01
3.2
1.9
—
—
—
0
0
34
116
2.85
7.01
3.2
1.9
—
—
—
0
0
97
520
1.89
6.96
1.5
1.4
219.10
336.49
u/ml
0.60
90
496
78
389
2.01
6.90
2.3
2.0
1.07
0.98
g/l
0.32
73
370
15
19
7.55
6.80
2.1
1.5
0.16
0.28
iu/ml
—
10
9
38
140
2.64
6.79
4.0
2.6
14.47
15.57
mu/l
0.21
38
129
21
54
3.74
6.75
4.9
5.9
23.14
23.31
umol/l
0.03
21
54
328
2436
1.56
6.71
5.8
3.4
181.44
1641.90
e6/l
—
9
29
548
4634
1.92
6.46
14.3
6.6
—
—
—
0
0
15
22
6.52
6.22
2.2
1.5
0.67
1.20
iu/ml
—
9
7
18
44
3.92
6.20
2.9
4.0
0.39
0.82
index
1.62
18
44
23
67
3.30
6.18
6.7
9.4
37.02
37.00
°c
0.17
23
67
16
27
5.67
5.99
5.4
3.3
—
—
—
0
0
237
1669
1.54
5.97
2.0
1.7
1.67
1.65
g/l
0.08
122
953
31
111
2.70
5.87
5.3
8.9
24.27
24.43
mmol/l
0.10
31
105
22
65
3.25
5.79
3.0
1.8
—
—
—
0
0
71
365
1.93
5.76
5.2
4.5
75.08
60.05
e9/l
1.81
50
189
48
214
2.19
5.70
6.0
10.1
248.70
362.33
mg/l
0.90
30
165
324
2456
1.49
5.64
6.4
3.4
36.03
27.53
u/l
2.21
319
2369
33
125
2.56
5.61
2.4
2.0
1.02
1.02
ratio
0.66
27
107
29
103
2.72
5.58
3.6
3.1
0.53
0.38
e9/l
0.49
20
52
280
2071
1.49
5.44
4.5
3.2
0.00
3.23
estimate
0.50
28
380
278
2057
1.48
5.37
4.5
3.2
0.00
0.00
estimate
-0.00
30
393
540
4608
1.75
5.27
18.8
9.1
23.52
23.45
mg/l
0.02
441
3310
5
0
+∞
5.09
1.0
0.0
—
—
—
0
0
278
2075
1.46
5.05
4.6
3.3
0.00
0.00
estimate
-0.00
28
377
19
56
3.25
5.03
1.1
1.1
—
—
—
0
0
34
138
2.38
5.03
3.0
3.6
—
—
—
0
0
19
58
3.14
4.77
14.9
3.3
—
—
—
0
0
30
118
2.45
4.75
2.6
5.0
—
—
—
0
0
42
192
2.13
4.71
1.5
1.3
—
—
—
0
0
52
259
1.96
4.64
2.7
1.9
—
—
—
0
0
23
80
2.76
4.63
1.3
1.5
317.12
375.90
ug/g
0.76
17
48
25
91
2.64
4.63
2.8
6.0
—
—
—
0
0
289
2207
1.43
4.47
4.4
3.3
62.37
62.86
ug/l
0.02
279
2111
74
418
1.75
4.46
1.6
1.5
—
—
—
0
0
23
82
2.69
4.43
2.5
4.7
—
—
—
0
0
599
5336
2.47
4.43
30.5
13.4
268.17
263.92
e9/l
0.83
585
5119
20
66
2.90
4.43
5.9
6.1
2.26
1.56
ug/l
0.64
20
66
599
5341
2.44
4.32
30.4
13.3
4.72
4.70
e12/l
0.62
581
5113
16
47
3.25
4.28
3.3
3.0
1.56
1.60
mmol/l
0.07
16
47
54
281
1.88
4.25
1.6
1.4
—
—
—
0
0
13
27
4.59
4.25
2.9
2.2
20.80
16.67
nmol/l
—
5
6
599
5346
2.41
4.22
30.5
13.3
6.97
6.87
e9/l
0.35
582
5119
18
58
2.97
4.16
6.2
5.0
—
—
—
0
0
17
53
3.06
4.14
2.7
2.1
—
—
—
0
0
64
359
1.75
3.97
1.7
1.3
137.80
148.76
u/ml
0.06
12
122
40
193
2.01
3.93
2.3
1.6
—
—
—
0
0
72
421
1.68
3.85
4.1
4.4
53.65
70.65
mg/l
0.31
54
345
105
1378
0.66
3.77
2.0
1.8
—
—
—
0
0
68
395
1.69
3.73
3.0
1.8
—
—
—
0
0
9
15
5.69
3.63
1.4
1.3
—
—
—
0
0
7
8
8.28
3.62
1.0
1.1
—
—
—
0
0
16
53
2.88
3.54
21.6
7.1
9.88
8.36
mg/l
0.37
16
47
9
16
5.33
3.47
1.3
1.1
31.22
27.06
s
—
9
16
71
427
1.63
3.42
4.3
4.9
5.60
40.59
mg/mmol
0.55
46
344
92
1218
0.66
3.41
2.2
1.9
—
—
—
0
0
43
225
1.85
3.37
2.7
2.0
—
—
—
0
0
10
21
4.52
3.36
3.8
6.0
151.60
212.05
ug/l
—
10
21
108
720
1.49
3.32
1.3
1.2
—
—
—
0
0
8
223
0.33
3.25
1.0
1.0
—
0.61
—
0
10
92
597
1.52
3.21
2.5
1.3
—
—
—
0
0
29
507
0.51
3.15
1.2
1.3
3.25
3.28
mmol/l
0.04
17
297
41
218
1.82
3.07
2.9
2.0
121.37
107.83
au/ml
0.28
19
79
22
94
2.24
2.98
2.2
2.1
2.23
5.29
iu/l
—
7
45
6
8
7.08
2.92
2.8
2.5
34.83
27.75
%
—
6
8
21
89
2.25
2.90
3.3
2.5
—
—
—
0
0
9
21
4.06
2.82
1.7
1.5
672.11
282.53
mu/l
—
9
21
19
79
2.29
2.75
4.5
2.0
1.73
2.40
mmol/l
0.64
11
65
9
22
3.87
2.71
1.7
1.5
72.78
75.27
%
—
9
22
229
1794
1.31
2.63
1.7
1.9
0.43
3.04
u/ml
6.75
43
360
38
580
0.59
2.60
1.5
1.7
1529.87
926.21
mu/l
0.42
29
535
136
991
1.37
2.54
4.0
3.1
0.00
0.00
estimate
0.50
29
360
94
645
1.43
2.49
2.5
1.3
—
—
—
0
0
95
656
1.42
2.44
2.5
1.3
—
—
—
0
0
95
657
1.42
2.42
2.5
1.3
—
—
—
0
0
47
280
1.62
2.40
9.7
5.5
0.90
0.79
%
0.12
20
83
11
36
2.90
2.37
1.1
1.2
278.09
260.71
mg/l
0.31
11
31
21
98
2.04
2.33
18.2
24.6
13.32
11.31
%
2.02
21
98
29
153
1.81
2.28
1.7
1.5
5.55
6.91
ug/l
0.28
29
146
5
8
5.89
2.26
2.6
3.6
—
—
—
0
0
5
8
5.89
2.26
1.4
1.3
13.20
10.00
mmol/l
—
5
8
11
38
2.74
2.23
1.0
1.0
—
—
—
0
0
11
38
2.74
2.23
1.1
1.1
—
—
—
0
0
94
661
1.39
2.18
2.5
1.3
—
—
—
0
0
12
45
2.53
2.17
18.1
5.6
97.67
86.64
mg/l
0.19
12
45
11
39
2.67
2.16
2.5
5.4
18.19
22.58
ug/l
0.96
11
39
5
9
5.24
2.11
1.0
1.0
—
—
—
0
0
5
9
5.24
2.11
1.0
1.6
—
—
—
0
0
5
9
5.24
2.11
1.0
1.1
162.40
138.67
mmol/24h
—
5
9
134
1002
1.32
2.10
1.9
1.7
—
—
—
0
0
16
70
2.17
2.10
1.7
1.2
—
—
—
0
0
48
298
1.55
2.09
1.3
1.2
—
—
—
0
0
44
268
1.58
2.08
7.4
5.0
0.68
0.49
%
0.31
19
78
18
83
2.06
2.08
1.7
1.4
—
—
—
0
0
13
52
2.37
2.07
3.4
3.4
47.25
32.23
mmol/l
0.85
13
52
26
137
1.81
2.07
1.9
1.7
0.13
0.00
estimate
—
8
53
19
90
2.01
2.05
5.1
10.7
65.76
612.83
mg/mmol
0.53
14
84
16
71
2.14
2.03
1.7
1.2
1.80
2.45
g/l
1.48
16
58
16
71
2.14
2.03
1.7
1.2
5.73
6.58
g/l
0.52
16
57
13
53
2.33
2.00
8.1
6.7
1.53
2.34
mmol/l
—
6
28
23
120
1.83
1.90
1.6
1.6
—
—
—
0
0
137
1559
0.77
1.90
1.9
1.8
—
—
—
0
0
128
966
1.30
1.88
6.3
4.4
—
—
—
0
0
45
284
1.52
1.85
2.0
1.9
6.39
6.39
ph
0.01
38
166
78
551
1.37
1.78
1.5
1.7
824.00
512.00
titre
—
10
90
158
1755
0.79
1.78
2.5
2.2
—
—
—
0
0
17
82
1.97
1.77
1.1
1.1
—
—
—
0
0
8
28
2.70
1.72
3.1
3.7
1.64
4.27
nmol/l
—
8
28
42
267
1.51
1.68
10.0
5.5
0.07
0.03
%
0.22
15
72
10
38
2.49
1.66
4.8
4.6
5.38
4.98
kpa
—
10
38
24
133
1.72
1.66
1.5
2.0
—
—
—
0
0
43
276
1.49
1.65
9.3
5.7
0.06
0.12
%
0.29
16
78
109
820
1.30
1.64
1.8
1.6
—
—
—
0
0
29
171
1.62
1.60
1.4
1.2
—
—
—
0
0
20
106
1.79
1.60
3.9
5.5
8.10
11.26
u/ml
0.25
20
106
9
35
2.43
1.47
1.0
1.1
—
—
—
0
0
6
20
2.83
1.47
1.3
1.9
1710.00
1621.50
ml
—
6
20
197
1607
1.22
1.47
1.6
1.7
—
—
—
0
0
7
26
2.54
1.46
1.0
1.0
—
—
—
0
0
12
55
2.07
1.44
4.3
3.6
2.40
1.68
%
—
5
19
21
307
0.63
1.28
6.8
2.7
—
—
—
0
0
8
34
2.22
1.23
1.0
1.1
—
—
—
0
0
8
35
2.16
1.20
3.1
2.1
102.00
98.37
g/l
—
8
35
33
217
1.45
1.18
1.1
1.2
—
—
—
0
0
8
37
2.04
1.13
4.0
2.4
—
—
—
0
0
7
29
2.28
1.10
1.1
8.2
—
152.05
—
0
20
36
245
1.40
1.08
1.4
1.2
—
—
—
0
0
118
945
1.21
1.06
3.4
3.9
87.34
111.19
ug/g
0.67
97
772
9
44
1.93
1.02
2.4
2.0
—
—
—
0
0
7
33
2.00
0.99
1.3
1.8
7.14
9.49
umol/l
—
7
33
0
27
0.00
0.98
0.0
3.9
—
—
—
0
0
67
510
1.26
0.97
1.5
1.5
—
—
—
0
0
20
126
1.50
0.91
1.2
1.0
—
—
—
0
0
42
305
1.31
0.88
2.8
1.8
171.43
152.86
u/ml
0.17
23
153
15
214
0.65
0.87
1.4
1.2
—
—
—
0
0
15
214
0.65
0.87
1.4
1.2
—
—
—
0
0
6
28
2.02
0.87
1.7
4.9
4.20
3.82
mmol/l
—
6
28
108
1162
0.84
0.86
3.6
2.4
0.00
0.00
estimate
0.50
20
323
14
82
1.61
0.86
1.1
1.1
—
—
—
0
0
8
43
1.75
0.83
13.3
7.3
5.30
4.88
pmol/l
—
8
43
175
1483
1.15
0.80
3.7
2.7
0.00
0.01
estimate
0.80
22
332
24
166
1.37
0.71
1.2
1.3
—
—
—
0
0
7
38
1.73
0.70
1.6
1.3
—
—
—
0
0
5
25
1.88
0.69
1.0
1.3
—
—
—
0
0
28
207
1.28
0.56
1.0
1.0
9.02
8.75
mu/l
0.08
22
174
19
133
1.35
0.55
1.1
1.6
—
—
—
0
0
36
277
1.23
0.53
1.5
1.8
—
—
—
0
0
37
286
1.23
0.52
1.1
1.1
6.63
10.11
u/ml
0.47
23
182
14
176
0.74
0.47
3.9
2.4
55.23
53.34
%
0.19
14
176
5
77
0.61
0.46
4.6
3.4
2.43
3.08
e9/l
—
5
77
13
88
1.39
0.46
2.7
3.3
135.00
134.18
g/l
0.05
13
76
24
278
0.80
0.45
1.5
1.5
61.48
60.34
ug/l
0.04
19
246
38
302
1.19
0.43
1.2
1.1
5.08
7.38
u/ml
0.36
25
201
5
30
1.57
0.42
1.6
6.5
—
—
—
0
0
0
14
0.00
0.41
0.0
2.0
—
—
—
0
0
5
31
1.52
0.41
1.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
2.1
—
—
—
0
0
8
56
1.34
0.40
1.1
1.3
—
—
—
0
0
64
537
1.13
0.38
1.2
1.3
—
106.18
—
0
22
22
168
1.24
0.37
1.3
1.6
1.55
4.04
u/ml
1.25
16
116
22
250
0.82
0.36
1.0
1.1
—
—
—
0
0
11
76
1.36
0.36
1.0
1.1
—
—
—
0
0
58
488
1.13
0.34
1.2
1.3
3.61
2.55
u/ml
0.32
43
347
34
275
1.17
0.33
1.1
1.1
0.57
0.42
u/ml
0.16
21
137
16
186
0.80
0.33
1.5
1.5
1.13
1.24
mm
—
10
146
17
196
0.81
0.32
1.5
1.5
—
—
—
0
0
20
154
1.22
0.32
1.3
1.2
—
—
—
0
0
55
467
1.11
0.29
3.0
2.6
7591.77
6140.39
u/l
0.09
13
182
11
130
0.79
0.26
1.8
1.8
14.87
5.86
u/ml
—
6
45
53
452
1.11
0.26
1.1
1.2
1.38
1.07
u/ml
0.18
37
316
51
434
1.11
0.26
1.1
1.2
4.29
3.11
u/ml
0.27
39
312
53
454
1.10
0.24
1.1
1.2
4.40
6.24
u/ml
0.52
37
346
20
160
1.18
0.23
1.0
1.0
3.07
3.32
kpa
0.24
13
132
31
258
1.13
0.23
1.4
1.2
—
—
—
0
0
18
196
0.86
0.21
1.4
1.6
—
—
—
0
0
6
45
1.25
0.20
1.0
1.1
2403.67
1685.84
miu/ml
—
6
45
20
163
1.15
0.20
1.2
1.1
—
—
—
0
0
20
163
1.15
0.20
1.0
1.0
—
—
—
0
0
20
163
1.15
0.20
1.0
1.0
-0.80
-1.86
mmol/l
—
6
26
20
163
1.15
0.20
1.0
1.0
7.06
7.36
kpa
0.24
13
134
6
48
1.17
0.19
1.5
1.6
—
—
—
0
0
48
416
1.09
0.19
1.7
1.4
—
—
—
0
0
7
56
1.17
0.18
1.6
1.8
—
—
—
0
0
10
113
0.83
0.17
1.5
1.3
0.41
0.55
ug/l
—
5
25
8
64
1.17
0.16
1.1
1.0
—
—
—
0
0
8
67
1.12
0.16
1.0
1.0
168.75
163.90
g/l
—
8
67
6
72
0.78
0.15
1.0
1.1
—
—
—
0
0
16
171
0.87
0.15
1.0
1.5
—
—
—
0
0
6
73
0.77
0.15
1.2
1.7
—
290.00
—
0
5
15
122
1.16
0.15
2.3
1.5
—
—
—
0
0
12
130
0.86
0.14
1.2
1.5
52.37
12.48
u/ml
—
7
103
135
1303
0.96
0.12
2.0
1.8
—
—
—
0
0
13
107
1.14
0.11
1.0
1.1
—
—
—
0
0
19
162
1.10
0.10
1.4
1.6
20.98
14.09
u/ml
0.12
13
107
6
50
1.13
0.09
1.0
1.1
29.35
36.45
iu/ml
—
6
50
6
51
1.10
0.09
1.0
1.1
—
—
—
0
0
50
449
1.05
0.08
1.2
1.2
0.99
7.38
u/ml
1.90
19
150
5
57
0.82
0.08
1.0
1.2
—
286.63
—
0
16
62
601
0.96
0.07
2.5
1.6
—
—
—
0
0
33
325
0.95
0.07
1.5
1.3
278.23
245.75
miu/ml
0.18
15
174
52
476
1.03
0.03
1.3
1.2
13.08
15.54
iu/ml
0.26
11
99
13
129
0.94
0.02
1.6
1.1
—
—
—
0
0
21
192
1.03
0.00
1.1
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
66.00
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
201.33
—
0
6
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
5
47
1.00
-0.00
1.2
1.8
8.18
6.37
mmol/l
—
5
47
0
6
0.00
-0.00
0.0
1.0
—
0.12
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
50.40
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
47
1.00
-0.00
1.4
1.1
—
—
—
0
0
5
54
0.87
-0.00
1.2
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
20.00
—
0
6
6
64
0.88
-0.00
3.5
3.8
14.83
29.20
u/ml
—
6
55
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint KRA_PSY_MOTOR_EXMORE and mortality.

Females

Parameter HR [95% CI] p-value
KRA_PSY_MOTOR_EXMORE 5.423 [3.53, 8.32] < 0.001
Birth year 0.999 [0.99, 1.01] 0.718

During the follow-up period (1.1.1998 — 31.12.2019), 51 out of 4619 females with KRA_PSY_MOTOR_EXMORE died.

Males

Parameter HR [95% CI] p-value
KRA_PSY_MOTOR_EXMORE 1.391 [1.09, 1.78] 0.009
Birth year 0.983 [0.97, 0.99] < 0.001

During the follow-up period (1.1.1998 — 31.12.2019), 74 out of 12381 males with KRA_PSY_MOTOR_EXMORE died.

Mortality risk

Mortality risk for people of age

years, who have KRA_PSY_MOTOR_EXMORE.

N-year risk Females Males
1 0.535% 0.22%
5 3.684% 1.348%
10 8.492% 3.597%
15 15.025% 6.466%
20 25.122% 10.711%

Relationships between endpoints

↥

Index endpoint: KRA_PSY_MOTOR_EXMORE – Motor disorders, excluding more controls

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data